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ABSTRACT
Scientific areas have utilized the exclusive qualities of nanomaterials for
medicine, diagnostics, drug delivery, tissue engineering and environmental protection.
Inorganic metal nanoparticles such as gold and copper have been widely studied in the
past decades. Due to the strong and tunable surface plasmon resonance (SPR),
nanostructures including nanoshells, nanorods, nanocages, and hollow nanospheres
exhibit strong optical absorption at near-infrared (NIR) wavelengths (650–900 nm),
resulting in resonance and transfer of thermal energies to the surrounding tissue to
raise the temperature. The absorbance of NIR light is desirable because it minimizes
thermal injury to normal tissues while providing optimal light penetration. The
efficient photothermal energy transfer effect by inorganic metallic nanoparticles such
as gold has been widely used for photothermal ablation of tumor tissues, as well as
drug delivery system for small molecules like protein, antibodies, DNAs, and small
interfering RNAs by NIR laser triggered-release.
Even though different kinds of gold nanoparticles have a great advantage on
the photothermal transaction and are promising for clinical applications, they are nonbiodegradable, raising concerns regarding their short/long-term metabolism and safety.
Tail vein injections of polyethylene glycol (PEG)-coated gold nanoparticles have been
reported to induce two phases of toxicity concerning inflammation in the liver. The
acute phase occurred immediately after administration of nanoparticles. The second
phase happened at 7 days post injection when the nanoparticles become localized in
the tissues, mostly in the liver and spleen after circulation in the blood. Due to
multiple valences of gold, redox reaction of gold within cells can increase the levels of

	
  

reactive oxygen species (ROS), which interferes with the mitochondrial membrane
potential. Disturbance of the mitochondrial membrane potential after exposure to gold
nanoparticles initiates an apoptotic cascade in cells.
It was also reported that three months after injection of PEG-HAuNPs, 11.4 ±
1.8 percentage of injected dose per gram (%ID/g) remained in liver, which was 70%
of the amount at one-day post injection. However, three months after injection of
PEG-HCuSNPs, the Cu level remaining in the liver was 1.1 ± 0.1 %ID/g, which was
only 5% of the amount at 1 day post injection. The Cu level in the liver decreases
much faster than Au level after 1 day, indicating faster metabolism and excretion of
copper nanoparticles than the gold nanoparticles.
Based on the previous research and findings, although gold nanoparticles have
more efficient photothermal transfer and more potential of future clinical usage for
tumor tissue ablation, they have a very slow metabolic and excretion rate, which leads
to acute and chronic in vivo toxicity. These findings support the hypothesis that
conjugating copper with gold nanoparticles will increase the in vivo excretion rate of
gold to reduce its toxicity while retaining the more efficient photothermal transfer
properties of gold nanoparticles for future clinical application.
Manuscript 1: Introduction to Metal Nanoparticles: Application in
Pharmaceutical Sciences (to be submitted to Materials Chemistry and Physics)
reviews the development and promising application of metal nanoparticles in
pharmaceutical and biomedical industry including, but not limited to, drug delivery, in
vivo imaging, in vitro diagnostics, therapeutics techniques, toxicity, etc.

	
  

Manuscript 2: Enhanced Cellular Clearance of Gold Nanoparticles by Copper
Sulfide Nanoparticles Through ATP7B as Transporter. (to be submitted to ACS
Nano) In this study, we use PEGylated hollow CuS nanoparticles (PEG-HCuSNPs) of
~70 nm in diameter as models to elucidate their highly efficient metabolic trafficking
in mouse liver. The Cu-ATPase transporter, ATP7B efficiently facilitates removal of
excess Cu ions in hepatocytes. ATP7B together with PEG-HCuSNPs-loaded
lysosomes move toward the apical domains of hepatocytes to transfer Cu into the bile
canaliculi through exocytosis. Moreover, primary cultured mouse hepatocytes exhibit
much higher efficient copper exocytosis than primary cultured mouse Kupffer cells.
Tail vein injections of polyethylene glycol (PEG)-coated gold nanoparticles have been
reported to induce two phases of toxicity concerning inflammation in mouse liver.
Conjugating copper with gold nanoparticles will increase the in vivo excretion rate of
gold to reduce its toxicity by fast metabolism and excretion rate of copper while
retaining the more efficient photothermal transfer properties of gold nanoparticles for
the future clinical application.
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format. This dissertation comprises of two manuscripts that have been combined to
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Manuscript 1: Introduction to Metal Nanoparticles: Application in
Pharmaceutical Sciences
This manuscript is being prepared for submission to Materials Chemistry and Physics.
Manuscript 2: Enhanced Cellular Clearance of Gold Nanoparticles by Copper
Sulfide Nanoparticles Through ATP7B as Transporter
This manuscript is being prepared for submission to ACS Nano.
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Abstract
Nanoparticles are small (<100nm) with high surface area to volume ratio, which
imparts many advantages such as easy surface modification and high loading volume.
Over the past few decades, metallic nanoparticles have emerged as important players
in the biomedical application field. They are widely used as high contrast agents in
bioimaging such as MRI, and serve as efficient delivery tools for gene therapy, cancer
drug delivery and big size biolabeling molecule transportation. Metallic nanoparticles
have represented an extraordinary platform for a distinct array of biological uses. This
review details the methods for synthesizing the metal nanoparticles, their application
in the biomedical field and their pharmacokinetic and toxicity issues.
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1. Introduction
Metal nanoparticles were widely used in making paints and glass panel
staining long before their properties have been discovered and understood. [1]
Precious metal, such as gold, has extensively been used and played crucial roles in
ancient China and Arabic medicine to treat rheumatoid arthritis. [2] Colloidal gold has
been used to treat alcoholism in the United States since the nineteenth century. [3]
Silver, another noble metal, also has been used as eye drops to prevent gonorrhea in
newborns from 1880s to the late 1900s [4]. After the successful synthesis of the
platinum compound in the 1960s, cisplatin has become one of the most extensively
used anticancer drugs, especially in the treatment of ovarian and testicular cancers. [5,
6] Since then, a plethora of literatures have been published to explain the recent
advances in nanotechnology [7- 11]. Nanoparticles demonstrate a useful platform with
enormous potential in cancer therapy and other biological applications. [12] Some
noble metal nanoparticles including gold have received increased attention from the
scientific community due to their distinctive properties and wide-range of applications.
The major current and most promising applications of metal nanoparticles include in
vivo and in vivo imaging, diagnostics, therapeutics, drug carrier and delivery,
biomaterials, biosensor and tissue engineering (Figure 1) [10].
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Figure 1. Application of metal nanoparticles in various biomedical fields

2. Methods for Preparation of Metal Nanoparticles
In order to prepare metallic nanoparticles with the preferred sizes and
morphologies, many methods including physical, chemical and green biological
approaches are used (some important methods are listed in Figure 2). Every method
has its advantages and drawbacks, which include using toxic solvents, expensive
materials, intensive labor and many others.
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Figure 2. Examples of physical, chemical and green biological methods for
metallic nanoparticle preparation

2.1 Chemical and Physical Methods
In chemical reduction method, different kinds of reducing agents including
sodium borohydride, ascorbate, sodium citrate, dimethylformamide, etc., are used to
reduce metal ions. [13-15] It is very important to use stabilizing agents throughout the
reduction process to protect the metallic nanoparticles from agglomeration and
sedimentation. [16] Polymeric compounds such as polyvinylpyrrolidone (PVP),
polyethylene glycol (PEG), and polymethacrylic acid, which comprise thiols, amines,
alcohols groups interact with particle surfaces to stabilize the final nanoparticles and
prevent them from growing and losing their surface properties.
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High-energy mechanical milling is a very effective physical method for
metallic nanoparticle synthesis. Fe−Cu nanoparticles have been successfully
synthesized using a ball-milling process that utilizes FeCl3 and CuCl2 [17]. Huang and
Yang reported that silver nanoparticles were prepared by using UV- initiated
photoreduction of silver nitrate in inorganic lay suspension at room temperature. [18]
Metallic nanoparticles prepared in the two-phase aqueous-organic system was reported
for silver nanoparticle synthesis. [19] The major disadvantage of this method is the
tremendous toxic organic solvents. Therefore, large amounts of surfactants and
organic solvents need to be separated and removed from the nanoparticles. In the
electrochemical synthetic method, the homogeneity and particle length of a
nanoparticle is easier to be controlled by modifying the composition of the electrolytic
solution and adjusting the electrolysis parameters. In one study, spherical silver
nanoparticles with narrow length distributions were prepared by this method, and poly
N-vinylpyrrolidone was used to protect nanoparticles from agglomeration [20].

2.2 Green Biological Methods
There is always a demand for using green biological methods to synthesize
metallic nanoparticles. Advantages of these methods include i) non-toxic and
inexpensive materials and solvents ii) less hazardous chemical process and waste iii)
cost-effective and iv) procedures can be done at room temperature. However,
disadvantages include i) limitations to repeat and scale up the massive production ii)
more studies are needed to elucidate the exact synthesis mechanism and iii) difficulty
producing the appropriate size and morphologies of the nanoparticles.
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Instead of organic solvents, polysaccharides (e.g., corn starch, dextran,
cellulose) and chitosan have been used for the green preparation of metallic
nanoparticles. It is reported that silver NPs were synthesized using polysaccharides as
capping agents and water as an eco-friendly solvent [21]. Polysaccharides have
hydroxyl groups and a hemiacetal-reducing end that can be used as a reducer. The
oxidation of hydroxyl groups in polysaccharides to carbonyl groups performs a crucial
role in reducing gold salts to form nanoparticles. Furthermore, the hemiacetalreducing end of polysaccharides can be used to stabilize metallic nanoparticles and
prevent sedimentation [22, 23]. For example, starch-stabilized and glucose-reduced
silver NPs with a mean diameter of 5.3 nm were prepared through the incubation of
silver salt with starch-stabilization and glucose-reduction at 40 °C for 20 h. [24].

3. Application of Metallic Nanoparticles
Nanoparticles have different shapes and a large surface to volume ratio. These
two advantages impart nanoparticles with the capability to actively interact with
proteins and cell membranes. Metal nanoparticles with localized surface plasmon
resonances (LSPRs) property offer more advanced ways for disease diagnosis and
treatments based on the resonant oscillation of electrons at the surface of the metal.
Besides nanoparticles with LSPRs property, other heavy metals and quantum dots also
have the potential to be used in diagnostic tests and as cell trackers and contrasting
agents. [25] Moreover, some of the metallic nanoparticles, such as gold and copper
have shown the extraordinary ability to be used in drug delivery and photothermal
therapy [26]. The application of metallic nanoparticles can be sorted into three
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interrelated areas: diagnosis, drug delivery and regenerative therapies.

3.1 Metallic Nanoparticles in Diagnostics
The application of metallic nanoparticles in diagnostics can be further
categorized into i) in vitro diagnostic tool by using nanoparticles as a probe for
disease-related biomarker detection and ii) in vivo imaging for in situ disease
monitoring.
Metallic nanoparticles made with semiconductor material have proved to better
bioprobes compared to conventional fluorescent probes. They are more
photochemically stable and have a more controllable symmetric emission spectrum.
[27] Gold nanoparticles have been used as a color marker for rapid pregnancy testing
since the 1980s. Collagen has been used as a biocoating to increase the
biocompatibility and improve the interaction with biomolecules, while also reducing
the degradation rate of nanoparticles. Metallic nanoparticles with localized surface
plasmon resonance (SPR) properties exhibit enhanced scattering and absorption light
at specific light wavelengths. [28] Gold nanoparticles have very good SPR property.
Within a protein-rich environment, the surface of gold nanoparticles can be conjugated
with different proteins. This binding process will increase the size of gold
nanoparticles and shift the SPR towards the longer wavelengths. This process can be
used for protein qualification and quantification. [29] As an application, specific
antibody-coated gold nanoparticles are applied to detect antigen at extremely low
concentrations in the nanomolar range, which cannot be achieved with current
diagnostic tools. This will identify subtypes of cancer earlier and promote the
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diagnosis and prognosis of cancers.[29]
In vivo imaging, such as magnetic resonance imaging (MRI), computed
tomography (CT), positron-emission tomography (PET), and single-photon-emission
computed tomography (SPECT) are widely used imaging instruments for monitoring
and diagnosing complex diseases, including cancer metastasis, and for monitoring the
different stages of cardiovascular disease. [30] Gold nanoparticles are
superparamagnetic compared to its bulk counterparts. It can be used as an MRI
contrast agent. Also, gold nanoparticles are high-resolution candidates for X-ray
contrast agents. They are reported to monitor the tumor-related microvasculature
progress in cancer metastasis. The leaky capillaries produced during metastasis allow
the gold nanoparticles to invade into the extravascular region of the newly malignant
tissue. [31]. Also, Zuo and his colleagues reported that the iron oxide nanoparticles
loaded with iRGD peptide nanocomplex can be successfully used as ultrasensitive
MRI contrast agent for the detection of pancreatic cancer. [32]

3.2 Metallic Nanoparticles in Advanced Drug Delivery
Drug delivery systems are designed to bring therapeutic agents to the target site
efficiently with minimum toxicity to healthy surrounding tissue. [33, 34] In regards to
the application of metal nanoparticles as a drug delivery system, they have to
overcome the reticuloendothelial system barriers such as macrophages. The
phagocytic removal of nanoparticles could limit the range of their application as
delivery tools in human biology and medicine. However, these nanocarriers surface
can be modified with polyethylene glycol to the surface. This coating will form a
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hydrated layer between proteins and nanoparticles, which reduces the risk of
opsonization by serum proteins and internalization of nanoparticles by phagocytes. [35]
Conventionally, chemotherapy target cancer cells by stopping cell division and
inducing cell apoptosis/necrosis. The healthy cells, however, will also be impacted by
chemotherapy, and as a result, the quality of life for patients is impaired significantly.
In this context, highly selective targeted delivery of chemotherapy is a key to efficient
cancer therapy and improving cancer patients’ quality of life. There are two strategies
used to reduce toxicity to healthy tissue during the targeted delivery of metal
nanoparticles to the cancer site: active and passive.
In active targeting, the surfaces of metal nanoparticles are conjugated with
ligands, whose receptors are expressed on the tumor cell surface. The high affinity
binding of the ligand and receptor will enhance the rapid internalization of the
nanoparticles. In passive targeting, blood vessels in tumor tissue have a high degree of
porosity because they lack angiotensin II receptors and pericyte coverage within
vessels, and this leads to the enhanced permeability and retention effect (EPR) [36].
The EPR effect allows nanoparticles conjugated with anticancer therapeutics to
penetrate into the extracellular tumor matrix from the tumor capillaries [37].
Besides being applied as drug delivery tools, nanoparticles are also emerging
as relatively simple and effective vectors for gene delivery due to their wide-range of
sizes, easier surface modification, higher loading capacity and better biocompatibility.
[38] Viral and non-viral gene transfer techniques have been widely used for gene
transfer. These methods, however, have innate drawbacks such as less efficient
transfer, higher toxicity and higher immunogenicity that limit their applications. As a
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gene delivery tool, metal nanoparticles protect DNA from degradation by nucleases
and facilitate the internalization of DNA into the nucleus. Guo and his colleagues
reported the feasibility of applying the charge-reversal functional gold nanoparticles as
a means of improving the siRNA delivery efficiency, and the final knockdown
efficiency was better than that of commercial Lipofectamine 2000. [39] Other
nanoparticles such as ion oxide, carbon nanotubes, magnesium phosphate and other
metal nanoparticles are also candidates for DNA delivery vehicles. [40]
Polyethyleneimine (PEI)-PEG-chitosan copolymer coated superparamagnetic ion
oxide nanoparticles (SPIO) were also reported to deliver the plasmid DNA into the
nucleus successfully and safely. [41, 42]

3.3 Metal Nanoparticles in Regenerative Therapies
Using stem cells to regenerate tissues and organs have revolutionized the
current techniques in organ transplantations. This better developed technique will be a
promising option to meet the needs of organ transplantation and save more lives.
Regenerative therapies using nanoparticles form a new area combining
nanotechnology and engineering. Tissues and organs developed by using stem cells
from an individual can be cultured in vitro and then transplanted back into the same
individual using a scaffold that the body’s immune system cannot distinguish to avoid
rejection [43,44]. Superparamagnetic ion oxide nanoparticles (SPIO) as described
above, are not only used to improve the safety and efficiency of gene delivery, but also
used to improve the detection sensitivity for MRI imaging. [45] The SPIO used for
MRI does not alter the function, proliferation or differentiation of hematopoietic stem

	
  

	
  

11	
  

cells (HSC) and mesenchymal stem cells (MSC) while being nontoxic and
biodegradable. [46]
Magnetic nanoparticles can be conjugated with specific antibodies for
selectively targeting stem cells, which express specific receptors for antibodies. The
stem cells then can be isolated and recovered by applying a magnetic field. Using this
“fishing technique”, Lui et al. reported the successful extraction and isolation of
stem/progenitor cells from the brain of rats by using antibodies conjugated to magnetic
nanoparticles (Ab-MNPs). These magnetically isolated stem cells are functional and
can be differentiated into different types of cells in vitro. This technique of
nanoparticle-mediated isolation and retransplantation of stem cells is now well
adopted for the treatment of leukemia and several cardiac diseases. [47]
Recently, immense attention has been placed on metallic nanoparticles as
scaffolds in bone regeneration. [48] The nanostructure size of bones is around 1 to 100
nm. Therefore, coating the artificial implants with nano-scaled materials before
transplantation would increase the biocompatibility and reduce graft rejection by the
immune system. Some bone morphogenic proteins (BMPs) have been reported to play
a crucial role in bone regeneration, especially in periodontal tissue [49]. They however
cannot be used directly due to inherent limitations such as local inflammation. In
recent years, gold nanoparticles have been used as a new generation of osteogenic
agents for bone. Heo and colleagues have developed a new approach for bone tissue
regeneration utilizing biodegradable hydrogel loaded with gold nanoparticles (GNPs).
The in vitro results show that GNPs loaded with hydrogels promote the differentiation
of human adipose-derived stem cells (ADSCs) into osteoblast cells. Moreover, the in
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vivo results show that the hydrogel nanostructure has a significant influence on the
new bone formation and can be useful for bone tissue engineering. [50]

4. Pharmacokinetics and Toxicity of Metal Nanoparticles
Recently, physiologically based pharmacokinetic (PBPK) modeling is widely
used by researchers to investigate the absorption, distribution, metabolism, and
excretion (ADME) of metal nanoparticles. The Organization for Economic
Cooperation and Development (OECD) and the new European Union regulatory
framework REACH (Registration, Evaluation and Authorization of Chemicals) have
published guidance, standards and quantitative tools for metal nanoparticle toxicity
tests, quantitative structure–activity relationship (QSAR) and PBPK models. [51]
The toxicological aspects of metal nanoparticles highly depend on its administration
routes, concentrations and exposure times. Exposure to high doses and high levels of
metal nanoparticles always induce toxicity. [52] Different routes of administration
lead to different organ accumulation of metal nanoparticles. Also, the blood supply
amount also plays an important role. After oral administration, nanoparticles may be
digested by gastrointestinal (GI) tract and excreted in feces. [53]. If the nanoparticles
are administrated through intraperitoneal (IP) and other injection routes, the
nanoparticles will be mostly absorbed into lymph nodes [54]. No matter which route
nanoparticles are administrated, most of them will be trapped in the reticuloendothelial
system (RES), especially in the liver and spleen. This can be reduced or decreased
however by coating the surface of nanoparticles with hydrophilic polymers such as
PEG. [55]. In addition to the liver and spleen, metal nanoparticles are also found in the
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GI tract, kidney, lung, heart, and brain. Metal nanoparticles also encounter different
proteins including the complement system in the blood. After coating with these
hydrophilic polymers, some of the metal nanoparticles such as copper sulfide can be
metabolized and excreted in the urine and feces. [56] Although researchers have
increased focus on the toxicity and applications of metal nanoparticles, studies on the
toxicity and adverse effects of metal nanoparticles are still in the early stages. The
toxicity of nanoparticles is largely based on the physiochemical properties such as
composition, morphology, shape, size and surface coatings. [57] These properties
could be attributed to the excessive presence of intracellular reactive oxygen species
(ROS) and the subsequent activation of pro-inflammatory genes. [58] The toxicity of
metal nanoparticle also depends on the cell types used in the studies. Patra et al.
reported that 33 nm citrate-capped gold nanospheres induced apoptosis in the human
carcinoma lung cell line A549. However, the two other cell lines tested, BHK21 (baby
hamster kidney) and HepG2 (human hepatocellular liver carcinoma), remained
unaffected by the same concentrations of gold nanospheres treatment. [59] With our
understanding of the metal nanoparticle, it is worth mentioning that the results of the
in vitro toxicity studies of metal nanoparticles cannot be extrapolated to the in vivo
toxicity studies or be used for clinical applications directly. In the future, establishing
a precise toxicological study platform for evaluating metal nanoparticles in medicine
is essential and required for improving its safety on human life.

5. Summary
The recent development of nanotechnology and material sciences has created a
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plethora of studies in metal nanoparticles. The results of these studies are widely
applicable in our daily lives, especially in the medical field for use in high contrast
imaging, drug delivery, and therapeutics. In the future, applications of metal
nanotechnology show great promise in improving our health and daily lives. The
attractive properties of metal nanoparticles such as their ability to be circulated in the
blood and translocated successfully into the nucleus due to their small size also make
them very dangerous. Diseases from the exposure to metal nanoparticles may not be
diagnosed immediately, but will manifest in the future. Many metal nanoparticles also
have low metabolic rates compared to their bulk counterparts. In short, metal
nanoparticles will have a huge impact on our lives in the future. Therefore, standards
and regulations should be created to protect us from the toxicity and adverse effects of
metal nanoparticles.
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ABSTRACT
Copper sulfide (CuS) nanoparticles show great potential in therapeutic and diagnostic
applications. Gold nanoparticles with bioinert properties have great advantages in the
photothermal transaction; however, gold nanoparticles are non-biodegradable, raising
concerns regarding their long-term metabolism and safety. Clinical translation of these
nanoparticles requires sufficient understanding of their metabolic process in vitro and
in vivo. Here, we use pegylated hollow CuS nanoparticles (PEG-HCuSNPs) of ~70 nm
in diameter as models to elucidate their highly efficient metabolic trafficking in mouse
liver and primarily cultured human and mouse hepatocytes. Traverse of Cu-ATPase
ATP7B to the nanoparticle-loaded late endosomes/lysosomes, as well as increased
ATP7B expression both in the cytosol and on the membrane at one hour following
PEG-HCuSNPs injection, show efficient removal of excess Cu ions by hepatocytes to
transfer content into bile canaliculi through exocytosis. With this finding, we
conjugated gold and copper nanoparticles and found that copper nanoparticles would
facilitate the excretion of gold nanoparticles through the transporter ATP7B. Primarily
cultured human and mouse hepatocytes exhibit much higher efficiency in terms of
exocytosis of PEG-CuSNPs-Au than Au alone, which is similar to the results found in
animal bile excretion study. These findings reveal that the high metabolic rate of the
systemically administered Cu in the liver could facilitate the excretion of gold
nanoparticles much more efficiently than gold administrated alone.

KEY WORDS: Copper sulfide nanoparticles, Au nanoparticles, Metabolism,
Hepatocyte, ATP7B
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Semiconductor copper sulfide (CuS) nanoparticles, a class of new
nanomaterials, have been widely reported for their biomedical applications in recent
years. The intriguing optical and physicochemical properties of CuS nanoparticles
endue them with great potential in cancer photothermal ablation therapy,1-4 drug
delivery,5-7 photoacoustic imaging,8 nuclear medicine9-12 and their combinations.7, 9-16
Although Cu is an essential element in the body, excess free Cu ions in excess are
toxic.17 A recent study has shown that CuS nanoparticles are much less cytotoxic than
copper oxide nanoparticles because of the extremely low solubility of CuS.18 Through
histological and biochemical examinations, we found that pegylated hollow CuS
nanoparticles (PEG-HCuSNPs) do not induce significant liver toxicity during the 3month study period.19 PEG-HCuSNPs exhibit a reversible change in the proteomic
profile in liver, offering long-term safety benefit.19 With the above evidence, we
believe that the slow dissociation rate of Cu ions from CuS nanoparticles, along with
effective mechanisms of Cu elimination, may allow physiological homeostasis to be
reached at an optimized dosing schedule without drastically increased toxicity.
Metabolism of CuS nanoparticles, accordingly, is critical to Cu homeostasis and
toxicity.
Existing pharmacokinetic analyses have shown that CuS nanoparticles can be
metabolized.11,

19

CuS nanoparticles, if smaller than the effective cut-off size for

glomerular filtration (~10 nm), are mainly excreted from the kidney.11 Ultra-small
CuS nanoparticles with hydrodynamic diameters less than 6 nm have minimally
nonspecific uptake by the mononuclear phagocyte system and highly efficient
clearance via the renal-urinary system.11 Comparatively, clearance of CuS
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nanoparticles larger than 10 nm is slower than that of the ultra-small CuS
nanoparticles.11, 19 We have previously demonstrated that about 67% of the injected
dose is eliminated from the liver within one month postinjection of PEG-HCuSNPs of
~70 nm in diameter.19 Therefore, liver is the major organ metabolizing these relatively
“large” CuS nanoparticles.11, 19 However, the mechanism of hepatic metabolism of
CuS nanoparticles remains unknown.
Even though different kinds of gold nanoparticles with bioinert properties have
a great advantage in the photothermal transaction and are promising for clinical
applications,

20, 21

they are non-biodegradable, raising concerns regarding their long-

term metabolism and safety.22, 24 Tail vein injections of polyethylene glycol (PEG)coated gold nanoparticles have been reported to induce two phases of toxicity due to
inflammation in the liver. The acute phase occurred immediately after administration
of nanoparticles. The second phase happened at 7 days when the particles become
localized in the tissues, mostly in the liver and spleen after circulation in the blood.25
Due to the multiple valences of gold, redox reaction of gold within cells can increase
the levels of reactive oxygen species, which interferes with the mitochondrial
membrane potential. Disturbance of the mitochondrial membrane potential after
exposure to gold nanoparticles initiates an apoptotic cascade in cells.26, 27
In this study, we use PEG-HCuSNPs as models to investigate their trafficking
in hepatocytes and Kupffer cells in vivo, and to elucidate their metabolic pathway in
mouse liver. It is generally believed that nanoparticles predominantly interact with and
are engulfed by cells of the mononuclear phagocyte system, such as Kupffer cells in
the liver, once these nanoparticles enter the blood.28 Distinctively, we find that the
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majority of PEG-HCuSNPs in liver accumulate in hepatocytes instead of Kupffer cells
following injection. The injected PEG-HCuSNPs undergo fast uptake and subsequent
disintegration in the endo-lysosomal compartments of hepatocytes, followed by quick
exocytosis into bile canaliculi with the assistance of the Cu-ATPase ATP7B. In
contrast, most engulfed PEG-HCuSNPs remain intact in Kupffer cells. Our findings
reveal that the hepatocytes play a major role in the metabolism of PEG-HCuSNPs,
which is distinct from conventional nanoparticle opsonization by mononuclear
phagocyte system, such as Kupffer cells. In comparison, Kupffer cells temporarily
store the CuS nanoparticles circulating in the blood, but with limited capacity. The
metabolism and excretion of PEG-HCuSNPs in hepatocytes are much faster than that
in Kupffer cells. Based on this finding in the study, we further conjugated gold and
copper sulfide nanoparticles with different kinds of physiochemical properties to study
the excretion of gold. It shows that conjugating copper with gold nanoparticles
enhance the in vivo excretion of gold nanoparticles to reduce their short and long term
toxicity, and reveal that the metabolic pathway of the systemically administered CuS
nanoparticles in liver could facilitate the excretion of gold nanoparticles much more
efficiently than gold alone.
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RESULTS AND DISCUSSION
Fast hepatobiliary excretion of PEG-HCuSNPs through efficient
nanoparticle trafficking into the bile canaliculi. To understand how PEG-HCuSNPs
were metabolized in the liver, we firstly collected bile samples from gall bladders at
different times following intravenous (i.v.) injection of the nanoparticles in BALB/c
mice. Transmission electron microscopy (TEM) illustrated that the nanoparticles
appeared in bile as early as 15 min after the administration (Fig. 1A). Interestingly, at
1 h post injection, in addition to the intact particles, there were many small
nanoparticles with diameters around 10 nm or less (arrowheads). At 4 h post injection,
one partially disintegrated PEG-HCuSNP is surrounded by many small CuS crystals
(yellow dash circle), suggesting that PEG-HCuSNPs may quickly break down during
the process of hepatobiliary excretion. Likewise, bile samples collected at 24 and 48 h
postinjection contained both large and small CuS nanoparticles. Noticeably, most
large CuS particles appeared to be partially disintegrated. We next centrifuged the bile
samples to separate the pellet (large and small CuS nanoparticles) from the
supernatant (Cu ions) for quantitative analysis of Cu. Figure 1B delineate a continuous
hepatobiliary excretion of Cu in both particulate and ionic forms within 1 week
following i.v. injection of PEG-HCuSNPs. Excretion of CuS particles in gallbladders
decreased over time, especially within 2 d postinjection. This could be attributed to the
decreased concentration of the CuS nanoparticles in the blood. In comparison, biliary
excretion of Cu ions remained relatively steady even after a week post injection.
We looked further into the nanoparticle distribution in mouse hepatocytes in
vivo. At 1 h post injection, the endo-lysosome loaded with CuS nanoparticles was
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found close to the nucleus (Fig. 2A), in which partially disintegrated large particles
(blue arrowheads), large particles with solid structures (orange arrowheads) as well as
decomposed small dots (green arrowheads) were present. Those large solid particles
consisted of highly packed small CuS dots, suggesting that the hollow structures of
PEG-HCuSNPs collapsed and the small CuS dots turned into aggregates during
degradation. These collapsed CuS nanoparticles were also found in the lysosome close
to the bile canaliculus (Fig. 2B, the structure pseudo-colored in light cyan), indicating
that the nanoparticle-loaded lysosome was moving toward the apical membrane of
hepatocyte for exocytosis. This hypothesis was further supported by the observation of
collapsed CuS nanoparticles was found in the bile canaliculi (Figs. 2C). Large solid
particles consisted of highly packed small CuS dots, suggesting that the hollow
structures of PEG-HCuSNPs collapsed and the small CuS dots turned into aggregates
during degradation (Fig. 2D and 2E). These results, correlating with the bile
distribution of Cu, indicate that the injected PEG-HCuSNPs underwent fast
endocytosis and disintegration in the endo-lysosomal compartments of hepatocytes,
followed by quick exocytosis into the bile canaliculi for efficient hepatobiliary
excretion.
Additionally after 1 h following i.v. injection of PEG-HCuSNP, Kupffer cells
were loaded with HCuSNPs. Lysosomes were found to fuse with the phagosome to
form a phagolysosome. (Fig. 2F, Kupffer cells Structures, pseudo-colored in pink).
The number of engulfed nanoparticles per vacuole was greater in Kupffer cell than in
hepatocytes (~20 nanoparticles in a vacuole in Fig. 2F vs. 3~5 incompletely
disintegrated nanoparticles in each vacuole in hepatocytes). Unexpectedly, most

	
  

	
  

30	
  

nanoparticles in phagosomes remained intact with hollow interior structures. Only a
few decomposed small CuS nanoparticles were observed in the phagolysosomes at 24
h postinjection (Fig. 2G, blue arrow head). This finding was different from the TEM
results of hepatocytes in which most nanoparticles were disintegrated or were
decomposed after 24 h. The intact morphology of the nanoparticles indicates that
metabolism of PEG-HCuSNPs in Kupffer cells was slow and minimal although their
phagocytosis was fast and efficient.
The swift disintegration of PEG-HCuSNPs may be ascribed to the interaction
between the nanoparticles and cellular components, facilitating the dissociation of Cu
ions. To prove this hypothesis, we prepared various media to investigate their effects
on Cu2+ release from PEG-HCuSNPs. As shown in Figure S1A, there was low
dissociation of Cu2+ dissociated from PEG-HCuSNPs in phosphate buffered saline
(PBS) due to the extremely low solubility of CuS.18 Addition of amino acids to the
medium significantly increased Cu2+ release, due to the formation of copper/amino
acid complexes.29 Interestingly, in PBS supplemented with cysteine (Cys) or Cys-HCl,
the Cu ion concentration at 24 h was lower than at 1 h or 4 h. This was because Cu2+
can induce the oxidation of Cys to cystine, thus precipitating the Cu.30 In addition,
glutathione (GSH) or metallothionine, considered to be part of the Cu storage
system,31 enhanced Cu ion dissolution (Fig. S1B). TEM confirmed that with GSHtreatment, PEG-HCuSNPs collapsed and transformed from hollow structures to solid
particles with small CuS particle dissociation (Fig. S1C, arrowheads). A similar
phenomenon was observed in PEG-HCuSNPs treated with metallothionine (Fig. S1D,
arrowheads). Also, media at lysosomal pH (pH 4.9)32 significantly increased
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dissolution of Cu ions compared to the physiological pH (Fig. S1E). These findings
supported the finding that cellular components such as amino acids and Cu storage
systems interacted with PEG-HCuSNPs to facilitate their dissociation and further
release of Cu ions. Acidic lysosomal conditions may also increase Cu dissolution from
the particles.
Efficient excretion of PEG-HCuSNPs by hepatocytes and Kupffer cells in
mouse liver. Distinct distribution patterns of PEG-HCuSNPs in hepatocytes and
Kupffer cells based on the TEM drove us to understand what roles the two types of
cells played in the metabolism of PEG-HCuSNPs. We thus investigated their
endocytosis and exocytosis in vitro by isolating primary hepatocytes and Kupffer cells
from mouse liver with high purity.19, 37, 38 (Fig. 3A) To mimic the in vivo condition, we
preincubated PEG-HCuSNPs with freshly collected mouse serum before treating the
cells for 1 h. After 30 min post endocytosis, primary hepatocytes and the Kupffer cells
reached a balance between endo/exocytosis of PEG-HCuSNPs. (Fig. 3B) After 30 min
post excretion, intracellular Cu was reduced by 90% compared to baseline, confirming
fast exocytosis of Cu by Kupffer cells. The hepatocytes also have high excretion
efficiency since Cu was reduced by 92.2% compared to baseline. However, only 0.17%
of copper was left in hepatocytes after 90 min post exocytosis versus 2% left in
Kupffer cells. These results demonstrate that both hepatocytes and Kupffer cells
exerted high excretion efficiency of PEH-HCuSNPs.
TEM of primary cultured mouse hepatocytes incubated with PEG-HCuSNPs in
intact mouse serum for 1 h showed that the nanoparticle-loaded late endosomes (Fig.
3C, white arrows) and lysosomes (arrowheads) distributed extensively in the
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cytoplasm. The nanoparticles in lysosomal compartments predominantly disintegrated.
In late endosomes with multivesicular structures, the nanoparticles also broke down
into small dots but with smaller amounts (Fig. 3C, white, pink and orange arrows).
Some decomposed CuS nanoparticles were in vacuoles inside the late endosome (Fig.
3C, orange arrows), suggesting that decomposition of nanoparticles occurred during
early-to-late endosomal maturation. Figure 3D illustrated that the nanoparticles were
excreted from hepatocytes through exocytosis. The nanoparticles either collapsed or
disintegrated in the exosomes (Fig. 3D, arrowheads). In the exosomes released directly
from the plasma membrane, the nanoparticles were indistinguishable because of light
electron dense (Fig. 3D, arrows). However, a great number of CuS nanoparticleloaded vesicles (Fig. 3E, arrows) appeared inside the multivesicular bodies fused to
the plasma membrane (Fig. 3E, the enlarged image with yellow margin) and excreted
out of the cell (Fig. 3E, the enlarged image with red margin). These findings proved
that the decomposed CuS nanoparticles were released from hepatocytes through
exocytosis by multivesicular bodies such as late endosomes or lysosomes. The results
of the TEM study were similar to the transwell endo/exocytosis study and confirmed
that excretion of CuS nanoparticles by hepatocytes occurred via lysosomal trafficking
to cytoplasmic membrane and extrusion into the bile canaliculi. The excretion rate of
CuS nanoparticles in hepatocytes was comparable to that in Kupffer cells, and less
remained in hepatocytes after 90 min post exocytosis.
Trafficking and expression of ATP7B in hepatocytes for Cu extrusion in
response to the injected PEG-HCuSNPs. Cu-transporting ATPase ATP7B, which is
highly expressed in hepatocytes, is crucial for maintaining Cu homeostasis.33 Under
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basal conditions, it transports Cu into the trans-Golgi network (TGN) for metallation
of many essential cuproenzymes or ceruloplasmin. Acute elevation of intracellular
copper, on the other hand, triggers ATP7B-dependent Cu sequestration and excretion.
ATP7B accumulates Cu and redistributes them from the TGN to late
endosome/lysosome compartments, followed by fusion with the apical plasma
membrane to extrude Cu ions into bile canaliculi.33-35 In order to investigate how
hepatic ATP7B respond to systemically injected PEG-HCuSNPs, we used fluorescein
isothiocyanate (FITC)-PEG5K-SH to label the nanoparticles. The FITC-conjugated
PEG-HCuSNPs (PEG-HCuSNPs-FITC) had less than 3.5% cumulative fluorescence
released in either acetate buffer (pH 4.9, lysosomal mimic) or PBS containing 10%
mouse serum over 24 h incubation (Fig. S2), suggesting the fluorescence labeling was
stable enough to track the nanoparticles in vivo. Figure 4A illustrated that fluorescence
of ATP7B (red) colocalized with fluorescence of the labeled nanoparticles (green) and
Rab7 (blue), a marker of late endosome/lysosome structures,36 in mouse hepatocytes at
1 h after i.v. injection (arrows). This result indicated that ATP7B indeed trafficked to
the nanoparticle-loaded vesicular compartments, participating in removal of intravesicular Cu.
We wondered whether any changes of cellular expression of ATP7B occurred
in hepatocytes. To find out, we isolated primary hepatocytes from BALB/c mice
following i.v. injection of PEG-HCuSNPs with our modified two-step collagenase
digestion method19, 37,38 Western blot results showed that at 1 h postinjection levels of
ATP7B protein increased by 30% in the cytosol and by 72% on the plasma membrane
of hepatocytes compared with basal levels, respectively (Figs. 4B and 4C). This
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finding showed that the liver quickly launched endogenous detoxification mechanism
in hepatocytes in the presence of high loading of PEG-HCuSNPs. Remarkably,
elevation of ATP7B on plasma membrane was substantially more than that in cytosol,
indicating that more ATP7B trafficked to the apical side membrane in order to
accelerate Cu ion excretion for homeostasis.33,

39

Nevertheless, the cytoplasmic

ATP7B declined to 71% at 4 h and further to 66% at 24 h compared to basal levels,
while membrane ATP7B returned to baseline. One possible explanation was that the
cellular storage of ATP7B was exhausted and production of ATP7B did not meet its
demand. Reduction of ATP7B would decrease the cellular capability of removing Cu
in hepatocytes, subsequently raising intracellular Cu ion level and causing potential
toxicity. This hypothesis was supported by the mRNA analysis that the Atp7b levels
declined to ~50% of baseline at 4 h postinjection (Fig. 4D). However, the mRNA
transcription restored at 24 h, indicating that hepatocytes quickly recovered from the
toxicity and regained ATP7B productivity. Concomitantly, protein expression of
cytoplasmic ATP7B was restored to baseline at 2 d postinjection, which was 1 d after
recovery of mRNA transcription (Fig. S3). Our previous study demonstrated a
reversible change in the proteomic profile of liver tissues in mice receiving PEGHCuSNPs through matrix-assisted laser desorption ionization-time-of-flight imaging
mass spectrometry (MALDI-TOF).19 The current results from ATP7B analysis, similar
to the previous result with proteomic profiling, confirmed that PEG-HCuSNPsinduced toxicity was transient and reversible at a therapeutic dose of 20 mg/kg of Cu.
Cuillel et al. disclosed the metabolic mechanism of CuO nanoparticles in
hepatocytes.40 The CuO nanoparticles underwent fast dissolution once it is delivered
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to endo/lysosomes after endocytosis. The burst release of Cu ions caused
destabilization/disruption of lysosomes, resulting in Cu2+ overload in the cytoplasm.
ATP7B played a key role in binding and removing Cu ions in cytosol.40 In contrast,
because of the extremely low solubility of CuS, dissolution of Cu ions from CuS
nanoparticles was slow.18 Significant amounts of CuS nanoparticles remained
undissolved in the endo-lysosomal compartment following endocytosis in hepatocytes
(Figs. 1B and 2). Noticeably, ATP7B was bound to the CuS nanoparticles in
hepatocytes at 1, 4, or 24 h postinjection by Western blotting analysis (Fig. 4E),
suggesting ATP7B participated in sequestering/chelating particulate Cu even before
Cu dissolution. Since ATP7B was observed to colocalize with the CuS nanoparticleloaded endo-lysosomes (Fig. 4A), in addition to transporting cytosolic Cu, ATP7B is
thought to cross the endo-lysosome compartment to chelate intra-vesicular Cu,
regulating both particulate and ionic Cu excretion into bile canaliculi.
Complement C3-mediated phagocytosis of the blood-circulating PEGHCuSNPs in Kupffer cells without significant degradation. When nanoparticles
enter the blood circulation, the nanoparticle’s surface is immediately covered with
blood proteins and peptides, forming a protein corona.41 The composition of the
protein corona determines the biological response to nanomaterials, directing further
tissue process of nanoparticles. To understand effects of nanoparticle-protein
interactions on the metabolism of PEG-HCuSNPs in vivo, we collected mouse blood
after i.v. injection of the nanoparticles. The nanoparticle-bound proteins were
identified by tandem mass spectrometry. Table 1 showed gene ontology classification
by the function of the nanoparticle-bound proteins from mouse plasma at 5 min or 1 h
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following injection. Compared to the nanoparticle-bound proteins at 5 min, the
number of proteins increased significantly in all 20 biological process categories at 1 h,
suggesting the formation of the protein corona on the surface of PEG-HCuSNPs
despite pegylation of nanoparticles. Classification of these bound proteins further
revealed that the three largest classes were the cellular process (383), biological
regulation (271) and metabolic process (251) at 1 h postinjection, all related to tissue
distribution and metabolism. Prominently, the number of metabolic proteins increased
from 6 at 5 min to 251 at 1 h postinjection, a highest 41.8-fold increase among all the
investigated classes. This result confirmed that proteins directly related to metabolism
were prone to binding to PEG-HCuSNPs in blood circulation, and involving the
metabolic process of the nanoparticles.
Characteristic of proteins bound to PEG-HCuSNPs would determine the in
vivo behavior of the nanoparticles and their biological outcomes.41,

42

We further

identified the 10 most abundant proteins adsorbed to PEG-HCuSNPs from mouse
blood at 5 min and 1 h postinjection, respectively (Tables 2 and 3). Complement C3, a
central protein in the complement system, was the most abundant protein bound to the
nanoparticles at both time points following administration. Remarkably, the
abundance of C3 among the adsorbed proteins at 1 h was 15.3 times that at 5 min. This
observation suggested that the complement system might play an important role in
mediating phagocytosis of PEG-HCuSNPs by macrophages, a phenomenon known as
opsonization.43-45
Several complement receptors expressed on Kupffer cells and hepatocytes are
responsible for the elimination of foreign nanoparticles in liver. Kupffer cells express
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the receptors for complement C3b, iC3b and C5a, while hepatocytes express C5a
receptors.46 Complement C3b and iC3b are products of C3 activation, while
complement C5a is a fragment of C5.

In order to confirm C3-coating on the

nanoparticles, we incubated PEG-HCuSNPs with 10% mouse serum followed by
centrifugation of the nanoparticles. The nanoparticle-bound proteins were then
isolated and analyzed by Western blot. Figure 5A illustrated that C3 and its fragment
C3b were apparent on the surface of PEG-HCuSNPs (Lanes 4 and 10). Compared with
untreated serum (Fig. 5A, Lane 6), C3 alpha chain and unknown fragments (37~50 kD)
were newly generated on the surface of PEG-HCuSNPs (Lanes 4 and 10). In contrast,
only C3 was clearly detected in the serum supernatant after incubation with PEGHCuSNPs (Fig. 5A, Lanes 3 and 9). By comparing Lanes 6, 3 and 4 in Figure 5A, we
found that serum C3b was transferred to the surface of PEG-HCuSNPs following
incubation. These results revealed that PEG-HCuSNPs significantly adsorbed C3 and
C3b in blood circulation and initiated the complement activation cascade to further
induce cleavage of C3 and/or C3b on the nanoparticle surface. This was possibly
attributed to CuS nanoparticles that might react with or chelate amino acid residues of
the adsorbed proteins. Since C3b and iC3b specifically bound to their respective
receptors expressed on the surface of Kupffer cells,43-45 significant uptake of PEGHCuSNPs by Kupffer cells was expected. In comparison, neither C3 nor its
fragmentation was detected on the surface of pegylated hollow gold nanospheres
(PEG-HAuNS), indicating that PEG-HAuNS did not adsorb C3 in the blood (Fig. 5A,
Lanes 2 and 8). This finding, consistent with other studies, confirmed that pegylation
of gold nanoparticles prevented C3-mediated opsonization.47 Results from Western
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blot analysis showed little to no complement C5 detected in PEG-HCuSNPs-bound
proteins (Fig. 5B, Lanes 4 and 10). PEG-HAuNS did not adsorb C5 in either mouse
(Fig. 5B, Lanes 2 and 8). These results demonstrated that C3-mediated opsonization of
PEG-HCuSNPs but not PEG-HAuNS in blood circulation. C5 adsorption on either
PEG-HCuSNPs or PEG-HAuNS was negligible.
We next assessed whether the C3-mediated opsonization facilitated
phagocytosis by the Kupffer cells. TEM of mouse liver showed PEG-HCuSNPs in
phagocytic vacuoles, namely phagosomes (Fig. 2F) were found to fuse with lysosomes
to form a phagolysosome. Unexpectedly, most nanoparticles in phagosomes remained
intact with hollow interior structures. Only a few decomposed small CuS nanoparticles
were observed in the phagolysosomes at 24 h postinjection (Fig. 2G). This finding was
distinct from the TEM results of hepatocytes in which most nanoparticles disintegrated
or were decomposed at 4 h postinjection. The intact morphology of the nanoparticles
indicated that metabolism of PEG-HCuSNPs in Kupffer cells was slow and minimal
although their phagocytosis was fast and efficient.
The process of opsonization was thought to rapidly eliminate the bloodcirculating nanoparticles (0.05--2 µm in diameter) in which Kupffer cells were the
major cell type involved in the liver.28,

48

Our results supported that significant

phagocytosis of PEG-HCuSNPs by Kupffer cells took place through opsonization by
nanoparticle-associated complement components such as C3 during the initial period
postinjection. When the time elapsed, the cellular Cu levels gradually decreased in
Kupffer cells. However, TEM results clearly showed that the phagocytized PEGHCuSNPs remained intact with a little degradation during 1 d of the investigation (Fig.
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2G). The excretion of the intracellular Cu may be attributed to exocytosis of PEGHCuSNPs by both hepatocytes and Kupffer cells, which was supported by the in vitro
transwell endo/exocytosis results showing fast excretion of PEG-HCuSNPs by both
hepatocytes and Kupffer cells. These evidence taken together indicated that Kupffer
cells might serve as a reservoir for storage of the blood-circulating PEG-HCuSNPs
without significant metabolism.
Metabolic pathway of PEG-HCuSNPs in liver following i.v. injection.
Based on the above results, we propose the itinerary of the metabolic process of PEGHCuSNPs in liver following i.v. injection as shown in Scheme 1. As soon as PEGHCuSNPs enter blood circulation, the nanoparticle’s surface immediately adsorbs
serum proteins and/or peptides forming a protein corona. The nanoparticles activate
complement component C3 but not C5 in situ. The complements C3 and C3b play a
key role in opsonization of PEG-HCuSNPs, facilitating their phagocytosis by Kupffer
cells through interaction between C3/C3b and their respective receptors. However,
Kupffer cells do not significantly metabolize the phagocytosed PEG-HCuSNPs but
use it for temporary storage. The engulfed PEG-HCuSNPs may be excreted into blood
circulation through exocytosis. On the other hand, the majority of PEG-HCuSNPs
pass through the sieve plate of the sinusoid followed by endocytosis by hepatocytes. In
contrast to Kupffer cells, hepatocytes quickly launch the endogenous detoxification
mechanism in the presence of high intracellular loading of CuS nanoparticles. The
nanoparticles either completely or partially break down into smaller CuS nanoparticles
in endolysosomal compartments. Cu ions also dissociate in the endocytic vesicles
during the nanoparticle’s disintegration, further released into the cytosol. Cu-ATPase
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ATP7B chelates the cytosolic Cu ions and redistributes from TGN to late
endosome/lysosome compartments that fuse with the apical plasma membrane to
excrete Cu ions into bile canaliculi. Moreover, ATP7B traverse the CuS nanoparticleloaded vesicles participating in the removal of intra-vesicular Cu through chelating
both particulate and ionic Cu. As a result, hepatocytes are the main force degrading
PEG-HCuSNPs from blood circulation and excreting Cu in both particulate and ionic
forms into bile. Kupffer cells in turn serve as a reservoir for transient storage of PEGHCuSNPs in order to reduce the Cu surge in blood. Both cells play different roles in
maintaining Cu homeostasis in the body.
Enhanced excretion of gold nanoparticles by HCuSNPs conjugation
through ATP7B.

We isolated primary hepatocytes from BALB/c mice by our

modified two-step collagenase digestion method19, 37, 38 with high purity (Fig. 3A). It
is reported that functional bile canaliculi can be detected by fluorescence microscopy
following 30 min incubation with 5 (6)-carboxy-2’,7’-dichlorofluorescein diacetate
(CDFDA), which can passively diffuses into hepatocytes, where it is hydrolyzed to
fluorescent carboxy-dichlorofluorescein (CDF) only by functional polarized
hepatocytes. After that, CDF is excreted into bile canaliculi.49 After 48 h incubation of
the seeded hepatocytes on collagen gel, much more CDF was formed and excreted
into bile canaliculi compared to the cells only incubated for 24 h. (Fig. 6A) The
ATP7B also correlative formed more after 48 h incubation compared to the 24 h
incubation, and stayed around the nucleus. (Fig. 6B) The above data denoted that the
perfused hepatocytes need 48 h to form ATP7B and for the polarized anatomy
structure-bile canaliculi to function properly. After that, we treated cells with PEG-

	
  

	
  

41	
  

HCuSNPs-RITC and CDFDA together and found that HCuSNPs colocalized with
CDF, which can be excreted into bile canaliculi. It suggested HCuSNPs were excreted
into bile canaliculi at last. Meanwhile, PEG-HCuSNPs-FITC was also colocalized
with ATP7B (Fig. 6C and 6D), denoted that HCuSNPs were excreted into bile
canaliculus facilitated by ATP7B.
With this finding, we then want to find out whether the excretion of HCuSNPs
can be used to enhance the gold nanoparticles excretion. Gold nanosphere (~40nm)
conjugated to the HCuSNPs (PEG-HCuSNPs@Au) (Fig. 7A) were used to treat
primary cultured hepatocytes with CDFDA. After 30 min incubation, PEGHCuSNPs@Au was colocalized with CDF and ATP7B, (Fig. 7B and 7C) however, in
PEG-AuNP group, CDF was excreted into the bile canaliculi without the PEG-AuNP
(Fig. 7B). Moreover, PEG-AuNPs after endocytosis were not colocalized with ATP7B
in the cultured hepatocytes and still stayed in cells. (Fig. 7C) The quantitative analysis
of gold exocytosis rate between PEG-AuNP and PEG- HCuSNPs@Au was also
studied using transwells seeded with mouse and human primary hepatocyte to mimic
the in vivo environment. In mouse primary hepatocytes, 36.10% of PEG-AuNPs were
excreted out in the first 30 min and kept at around 15% after 60 min exocytosis
process, however, 55.10% of PEG-HCuSNPs@Au were excreted in the first 30 min
and keep at around 8% after 60 min exocytosis. (Fig. 8A and 8B) In human primary
hepatocyte, 36.64% of PEG-AuNPs were excreted in the first 10 min and kept at
around 35% after 60 min exocytosis. PEG-HCuSNPs@Au excreted 54.47% in the first
10 min and kept at around 17% after 60 min exocytosis. (Fig. 8C and 8D) It suggested
from the mouse and human primary hepatocytes transwell studies that PEG-
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HCuSNPs@Au had a much faster excretion rate than the PEG-AuNPs alone.
Meanwhile, less gold was left after 60 min excretion in the PEG-HCuSNPs@Au
treated group, which denoted that HCuSNPs not only increased the gold excretion rate,
also enhanced the clearance of gold from the hepatocytes significantly and had less
gold residue within cells. We looked further into the in vivo PEG-HCuSNPs@Au
nanoparticles excretion. Bile samples collected from gall bladders at different times
following intravenous (i.v.) injection of the PEG-HCuSNPs@Au nanoparticles in
BALB/c mice. Transmission electron microscopy (TEM) illustrated that the
nanoparticles appeared in bile as early as 15 min after the administration. Particles
were also seen in 30 min, 1 h, and 4 h time points. (Fig. 9)
Besides the gold sphere, we also synthesized gold nanorod (AuNR) (~40nm)
and AuNR conjugated with CuSNPs(~5nm) (PEG-AuNR@CuS) (Fig. 10A) to
compare the excretion process between gold nanorod and PEG-AuNR@CuS. At 5 min
after the CuSNPs treatment, PEG-CuSNPs already colocalized with ATP7B, which
moved from cytosol to along with the bile canaliculi in a fast rate. The same
observation happened in the PEG-AuNR@CuS treated group. (Fig. 10B and D)
However, after 35 min treated with PEG-AuNR alone, the nanorods were still within
the hepatocytes and not overlap with ATP7B. (Fig. 10C) After 35 min incubation with
CDFDA, PEG-CuSNPs and AuNR@CuS were excreted into bile canaliculi together
with CDF. However, PEG-AuNRs were still within hepatocytes. (Fig. 10E) It
suggested that conjugating PEG-AuNR@CuS facilitated the excretion of PEG-AuNR
into bile canaliculi. Meanwhile, the exocytosis rate of gold was compared between
PEG-AuNR and PEG-AuNR@CuS using transwells seeded with primary cultured

	
  

	
  

43	
  

mouse and human hepatocytes to mimic the in vivo environment. In mouse primary
hepatocyte, in the PEG-AuNR treated group, 38.3% of gold were excreted out in the
first 10 min and still 10% left after 60 min exocytosis, However, 87.7% of gold in the
PEG-AuNR@CuS treated group were drained in first 10 min, and less than 1% left
after 60 min exocytosis. (Fig. 11A and 11B) The fast excretion rate of PEGAuNR@CuS also happens in human primary hepatocytes. In the PEG-AuNR treated
group, 59.6% of gold were excreted out in the first 10 min and still 1.5% left after 60
min exocytosis, However, in the PEG-AuNR@CuS treat group, 80.5% of gold in the
AuNR@CuS treated group were drained in first 10 min, and less than 0.7% left after
60min exocytosis. (Fig. 11C and 11D). Based on the transwell endo/exocytosis study,
even though we synthesized gold and copper sulfide nanoparticles in different sizes
and shapes, the exocytosis rate of gold will increase dramatically after conjugation of
gold and copper sulfide nanoparticles compared to gold nanoparticles only.
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CONCLUSION
In conclusion, we clearly elucidated the liver metabolic pathway of PEGHCuSNPs in which hepatocytes played a major role in taking up, degrading and
eliminating the nanoparticles through efficient hepatobiliary excretion. Cu-ATPase
ATP7B were the key transporter participating in the removal of excess Cu in both
particulate and ionic forms through trafficking toward the apical membrane of
hepatocytes. In contrast, metabolism of PEG-HCuSNPs in Kupffer cells was minimal
although their phagocytosis was significant through opsonization. The function of
Kupffer cells was likely to reduce the copper surge in blood through storage of the
nanoparticles, but with limited capacity. Additionally, apply the fast metabolism and
clearance rate of CuSNPs, it was not only increased the gold excretion rate, also
enhanced the clearance of gold from the hepatocytes significantly after conjugating the
AuNPs with CuSNPs. Our findings will give deeper insight to understand the
relationship between metabolism and toxicity of CuS nanoparticles in the
hepatobiliary system and also the application of its advantage properties such as fast
metabolism to enhance to clearance of other heavy metallic particles.
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EXPERIMENTAL SECTION
Materials. Chemicals were ordered from Sigma-Aldrich Co. LLC. unless
described specifically. The primary hepatocytes are cultured with Williams' Media E
(WEM, Fisher Scientific) that was supplemented with 10% FBS and 1% penicillinstreptomycin. BALB/c mice were purchased from Jackson Laboratory, Inc. All animal
experiments were performed under protocols approved by the University of Rhode
Island and Fudan University Institutional Animal Care and Use Committee (IACUC).
Synthesis of HCuSNPs. The HCuSNPs were synthesized according to a
previously reported method with minor modifications.50 CuCl2 solution (500µL,
0.5mol L−1) was added to deionized water containing poly-(vinylpyrrolidone) (PVPK30,) in a round flask under magnetic stirring at room temperature. Then, NaOH
solution (25 mL, pH 9.0) was added to the mixture. After stirring for 5 min, hydrazine
anhydrous solution was added to form a suspension of Cu2O spheres. Another 5 min
later, freshly prepared Na2S aqueous stock solution (2.5 mL, 320 mg/mL) was added
to the suspension. The flask was heated for 2 h at 60°C with magnetic stirring. After
incubating overnight at room temperature, the HCuSNPs were centrifuged at 11,000
rpm for 15 min at room temperature, and washed twice with distilled water. HCuSNPs
was resuspended in 4.8 mL of water mixed with 200 µL of Methoxy-PEG5K-SH (20
mg/mL,) overnight at room temperature to obtain PEG-HCuSNPs. The nanoparticles
were then washed twice with distilled water and stored at 4 °C for future use.
Synthesis of Au-nanorod (two-step method) Au-nanorod was synthesized
according to a two-step method with modifications.51, 52, 53

1) Seed Synthesis The

synthesis was performed in a 27°C water bath. After adding 25 µl of 50 mM HAuCl4
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solution to 4.7 ml of 0.1 M CTAB, the mixture was slowly stirred for 5 min. Then,
300 µL of a freshly prepared 10 mM NaBH4 was rapidly injected under vigorous
stirring. After 20 seconds, the solution (light brown color) is gently stirred and
incubated for 30 min before use.

2) Synthesis of Au nanorod Ten ml of 0.01 M

HAuCl4 solution was added to 190 ml of 0.1 M CTAB. The mixture is gently shaken
and incubated 10 min in a 27°C water bath to ensure uniformly mixed between gold
salt and CTAB. Afterwards, ascorbic acid solution (1.1 mL, 0.1 M) is added to the
mixture, which was gently shaken for few seconds until the solution turned colorless.
A solution of AgNO3 (1.6 mL, 0.01 M) was then added to the solution, which was
shaken for few seconds. Finally, the seeds solution (240 µL) was added to the mixture
and the solution was vigorously shaken and left undisturbed in a 27 °C water bath
overnight. The OD of the solution was checked by wavelength scan and the peak was
around 750 nm. The size was around 40 nm, as determined by TEM conformation.
Synthesis of Au-nanosphere Five grams of chlorauric acid in 95 mL of
solution was heated to the boiling point with stirring and 5 mL of 10 mg/mL sodium
citrate solution was added to the boiling solution. After about a minute of stirring, a
very faint greyish-pink tone appeared, which gradually darkened over a period of
about 10 min. The final color of the solution was deep wine red.54
Synthesis of AuNR@CuS conjugation In day one, 0.5 mg of Au rod
(prepared according to above method) was mixed with 1 mg of SH-PEG5K-Methoxy
and 0.1 mg of SH-PEG5K-COOH in 1 mL Millipore water. Then the mixture was
sonicated for 10 min and left on the rotor plate for overnight at room temperature. On
day two, a 50°C water bath was prepared before the synthesis process. In a 50 ml
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falcon tube, added 9 ml of ddH2O was added and stirred. The following reagents were
sequentially: (100 µL, 100 mM) CuCl2, (50 µL, 5 mg) SH-PEG5K-M, (1 mL, 6.1 mg)
GSH. The pH of the mixture was adjusted with NaOH to pH 9.3. Then the mixture
was vented with argon for 5 min, followed by addition of thioacetamide. After that,
the mixture was kept in a 50 °C water bath with magnetic stirring for 2 h, then the
CuSNPs was condensed for 15 min, 4000 g in swing bucket, and then the condensed
particle was resuspended in diH2O.55
On day two, the PEG-AuNRs was activated with 0.4 mg (3-Dimethylaminopropyl)-Nethylcarbodiimide hydrochloride (EDC-HCl) and 0.6 mg N-Hydroxysuccinimide
(NHS) and placed on the rotor plate to activate for 1 h at room temperature. After
activation, AuNRs were centrifuged for 10 min at 14,000 rpm and the supernatant was
discarded. The AuNRs were washed in cold MES twice. Then the pellet was washed
in 1 mL 1XPBS and centrifuged for 10 min at 14,000 rpm. One mL of AuNRs was
added to 4 mL of CuSNPs. After 15 min sonication, the mixture was placed on the
rotor plate for 24 h mixing at room temperature. On day three, the mixture was
centrifuged at 11000 rpm for 10 min to remove the unconjugated CuSNPs. Then the
pellet was washed for twice and stored in 100 µL of diH2O at 4°C.
Synthesis of PEG-HCuSNP@Au conjugation. The PEG-HCuSNP@Au
conjugation underwent a one-step synthesis according to a previous publication with
modification.56 One mL of HCuSNPs suspension as prepared above was dispersed in
1.2 mL ethanol, followed by the addition of 10 mg PVP-K30. After stirring for 30
min, 9.6 mL HAuCl4·3H2O aqueous solution (0.3 mM) was added and the mixture
was stirred for 10 min. Afterward, 0.5 mL NaBH4 (3 mM) was added and the mixture
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was stirred for another 30 min. The products were collected by centrifugation at 11000
rpm for 15 min and washed three times with ethanol. Then, the PEG-HCuSNP@Au
conjugations were resuspended in water and coated with SH-PEG5K-Methoxy.
Excretion of PEG-HCuSNPs into gall bladders in mice. BALB/c mice were
divided into 7 groups (n = 3 - 4). One group of mice injected with saline were used as
blank control. The other 6 groups received i.v. injection of PEG-HCuSNPs (20 mg/kg
body weight of Cu). At 1 h, 4 h, 24 h, 2 d, 4 d, or 7 d post-injection, the gallbladder of
each mouse was collected. The content of each gallbladder was then centrifuged at
13,523 g for 15 min to separate the pellet (CuS nanoparticles) and supernatant (Cu
ions). The supernatant of each sample was directly added to a 2% nitric acid solution
for inductively coupled plasma mass spectrometer (ICP-MS) analysis (Model: X7,
Thermo Electron Corporation) of Cu. The pellet was added with nitric acid and
digested by Mars 5 microwave system (CEM Corporation), 0.2 mL of which was
added to 9.8 mL of deionized water for ICP-MS analysis. In a parallel study, the pellet
was resuspended in water and directly deposited on the Formvar-coated nickel grid
(200 mesh, Ted Pella, Inc.) without counterstaining. The samples were examined
under TEM (JEOL, JEM2100).
Isolation of Primary Mouse Hepatocytes and Kupffer Cells. Primary mouse
hepatocytes and Kupffer Cells were isolated by a two-step collagenase perfusion.
After perfusion mouse liver was excised and finely broken into small pieces by
forceps in washing buffer. The resulting cell suspension was passed through a 40-mm
cell strainer to remove undigested tissue. The resulting single-cell suspension was
obtained and transferred to a 50 ml conical tube and centrifuged at 50 g for 5 min at 4
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°C. The supernatant was saved for the non-parenchymal cells (NPC) including
(Kupffer Cells) purification. The hepatocyte pellet was further purified with 100%
Percoll (GE). After washing, the high-purified hepatocytes were resuspended in
culture medium for future use.57 The NPC (including Kupffer cells) was centrifuged at
650 g for 7 min at 4 °C. The collected pellets (NPC) were purified with 50% Percoll
to remove blood cells. For Kupffer Cells purification: 10 µL PE-conjugated anti-F4/80
antibody was added in the dark for 15 min at 4 °C, then washed with 1mL BPE
(phosphate-buffered saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2
mM EDTA) and centrifuged at 650 g for 7 min at 4 °C. The pellet was resuspended in
100 µL BPE and 20 µL anti-PE beads and incubated in the dark for 15 min at 4 °C. It
was then washed with 1 mL BPE, and centrifuged again at 650 g for 7 min at 4°C. The
supernatant was removed and the pellet was resuspended in 500 µL BPE. After that,
the column was placed in the magnetic field of the MACS separator. After rinsing the
column with 500 µL BPE, 500 µL cell suspension was applied to the column. Kupffer
Cells were collected after the unlabeled cells were washed out.58
Proteomics analysis of PEG-HCuSNPs-bound proteins. Two groups of
BALB/c mice were i.v. injected with PEG-HCuSNPs (20 mg/kg of Cu). After 5 or 60
min, the mouse blood was collected in Eppendorf tubes containing 109 mM of sodium
citrate (100 µL) as an anticoagulant, and centrifuged at 845 g for 5 min to obtain the
mouse plasma, followed by a second centrifugation at 1,503 g for 3 min to further
remove red blood cells. A third centrifugation at 1,503 g for 6 min resulted in a CuS
pellet. The CuS pellet was washed with PBS once, then with 20 mM Tris-MOPS
buffer (pH 7.4) for 6 times. Afterward, 50 µL of reducing buffer (62.5 mM Tris-
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hydrochloride, 20 mM dithiothreitol, 2% sodium dodecyl sulfate, 20 mM EDTA, pH
6.8) was added to disperse the washed CuS pellet. The dispersion was heated at 70 °C
for 10 min to detach the absorbed proteins from the nanoparticles. A centrifugation at
12,851 g for 10 min was performed to collect the supernatant for proteomic analysis.
Preparation of nanoparticle-bound proteins for Western blotting analysis.
One hundred microliters of freshly collected mouse serum were added to 500 µL of
PBS. Then, 400 µL of PEG-HCuSNPs (1 mg/mL of Cu) or PEG-HAuNS (1 mg/mL of
Au) were added to the above PBS and incubated for 1 h at 37 °C on the rocker. After
incubation, the samples were centrifuged at 12,851 g for 10 min to separate the pellet
and supernatant. The supernatant was directly used for Western blotting analysis.
After washed with 20 mM Tris-MOPS buffer (pH 7.4) for 6 times, the pellet was
dispersed in 50 µL of reducing buffer (62.5 mM Tris-hydrochloride, 20 mM
dithiothreitol, 2% sodium dodecyl sulfate, 20 mM EDTA, pH 6.8) and heated at 70 °C
for 10 min to detach the absorbed proteins. A centrifugation at 12,851 g for 10 min
was performed to collect the nanoparticle-bound proteins in the supernatant for
proteomic analysis.
CDFDA Assay. The mouse primary hepatocytes were cultured for 48 h in a
collagen-coated petri dish. The hepatocyte and bile canaliculi function was assessed
by visualization of excreted fluorescent products after incubation with 5-(and-6)carboxy-2′,7′- dichlorofluorescein diacetate (carboxy-DCFDA) at a final concentration
of 2 µM. Carboxy-DCFDA molecule can passively enter the cytoplasm of functional
hepatocytes, where esterase metabolizes it to a fluorescent product that is then
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excreted into the bile canaliculi only by functional hepatocytes. The cell nuclei were
counterstained using Hoechst 33342.59
Confocal Study of Nanoparticles Excretion Process. Mouse primary
hepatocytes were cultured in collagen coated 35-mm petri dish. After 48 h incubation,
cells were treated with 10 µg/mL of different kinds of nanoparticle-FITC for 5 min, 15
min and 35 min. The cells were stained with rabbit anti mice antibody ATP7B (Santa
Cruz) and counterstained with goat anti rabbit- Alexa fluor-555 (Invitrogen). The cell
nuclei were counterstained using DAPI (Sigma). Confocal fluorescence images were
obtained with a Zeiss axioimager M2 imaging system with Zeiss LSM 700 confocal
module.
Primary cultured hepatocytes and Kupffer cells on Transwell for
Endo/Exocytosis Study 1) Endocytosis: Transwells were coated with 50 µg/ml type
I collagen in 0.02 N glacial acetic acid. The transwells were incubated for one hour at
room temperature and then washed with a 4 fold volume of 1X PBS. Then transwells
were coated with 1.5 mg/mL collagen and incubated in the cell culture incubator for
15 min. A single layer of hepatocytes was seeded two days before the experiment. In
the upper chamber, 500 µL cell culture media was added and 1500 µL of cell culture
media was added to the lower chamber. Nanoparticles (10 µg/mL) were incubated
with WME with 2% mouse serum final concentration for one hour. The apical side
media was aspirated and replaced with 500 µL of nanoparticles included media and
incubated for 5 min at 37 oC. The apical medium was removed and washed twice with
ice-cold PBS to stop the endocytosis process. After washing the insert, 100 µL of
CelLytic M cell lysis reagent was added to the apical side of the transwells. The cell
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lysate was collected and transferred into a 1.5 mL Eppendorf tubes. Then, the lysate
was centrifuged at 13,523 g for 10 min and the supernatant was removed from the
pellet and stored at 4 oC separately.

2) Exocytosis: Endocytosis is the same process

as described above. After 5 min incubation at 37 oC, media with nanoparticles in the
upper chamber side was aspirated and quickly washed with 500 uL warm WME once,
and then 500 µL of fresh cell culture media was added into the upper chamber side.
The cell culture insert was transferred to another well with 1.5 mL of cell culture
media. After 10 min, the upper chamber media was aspirated and washed with 500 µL
of warm WME on both sides. Then 100 µL CelLytic M cell lysis reagent was added to
the upper chamber and cell lysate was transferred into a 1.5 mL Eppendorf tubes.
After another 30 min and 1 h, the above exocytosis step was repeated. The collected
cell lysates were centrifuged at 13,523 g for 10 min, and the pellet was moved from
the supernatant for the ICP-MS analysis.
ICP-MS Analysis The endo/exocytosis samples were dissolved in 4 parts
HNO3 and 1 part HCl overnight for digestion. Before loading the sample to the
inductively coupled plasma mass spectrometer (ICP-MS) (Model: X7, Thermo
Electron Corporation) for quantitative analysis of Cu or Au, the solvent was diluted to
2% HNO3 / 2% HCl. The calibration standards of Cu and Au have six concentrations
(0.1, 0.25, 1, 25, 50, 100, and 200 ppb) and were analyzed with each batch of
samples.19
Preparation of tissue samples for TEM. BALB/c mice were i.v. injected
with PEG-HCuSNPs (20 mg/kg of Cu). At the predetermined time points, the mice
were euthanized and the liver was quickly collected, cut into 1 mm3 and fixed in the
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fixation reagent (2.5% glutaraldehyde plus 2% paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4). The TEM sample preparation followed routine procedure. The
samples were embedded in Epon resin followed by ultrathin sectioning (60-70 nm
thickness). The sections were placed on nickel grids with formvar/carbon film stained
with 7% uranyl acetate and lead citrate. The samples were examined under TEM
microscope (FEI Tecnai Biotwin, LaB6, 80 kV).
Immunofluorescence staining. BALB/c mice were i.v. injected with PEGHCuSNPs-FITC (20 mg/kg of Cu). At the predetermined time points, the mice were
euthanized and the liver was quickly collected, and embedded in O.C.T. for
cryosectioning (8 µm thickness). Tissue sections on slides were fixed in 95%
methanol or acetone (10 min, -20°C), rehydrated in PBS, blocked in 2% BSA-PBS0.15% Triton X100 (30 min), labeled with primary antibody (overnight, 4°C) and then
secondary antibody (1 h, room temperature). Goat anit-ATP7B primary antibody from
Santa Cruz Biotechnologies was diluted into 1:50 before use. Rabbit anti-Rab7
primary antibody from Abcam was diluted into 1:300 before use. CFL405 conjugated
donkey anti-rabbit IgG (1:100) and CFL555 conjugated donkey anti-goat IgG (1:200)
secondary antibodies were purchased from Santa Cruz Biotechnologies. The
immunofluorescence-stained sections were examined under a ZEISS LSM 710
confocal microscope equipped with a 63x1.4 numerical aperture oil objective and
ZEISS ZEN 2012 software.
Preparation of membrane and cytosol fractions of hepatocytes. Membrane
and cytoplasmic fractions from the perfused primary hepatocytes in mouse at different
times following injection of PEG-HCuSNPs (20 mg/kg of Cu) were prepared as
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previously described with some modification. Approximately 100 mg of mouse
primary hepatocytes were lysed and homogenized in 900 µL of sucrose-Tris (pH 7.2)
buffer containing 250 mM of sucrose, 1 mM of EDTA, 10 mM of Tris HCl, and
protease inhibitors (100x Halt Protease and Phosphatase Inhibitor Cocktail,
ThermoFisher). The homogenates were sonicated for three times (10 s per pulse, 30 s
interval). The lysates received first centrifugation at 500 g for 10 min to remove
cellular debris. A second centrifugation at 6,000 g for 10 min was used to pellet the
CuS nanoparticles. A third centrifugation at 100,000 g for 60 min was applied to
separate cytosolic fractions from the lysates. The pellets were then washed with 900
µL of sucrose-Tris buffer and centrifuged at 100,000 g for 60 min. After washing, the
pellets were suspended with 50 µL sequential extraction kit reagent 3 (Bio-Rad), and
centrifuged at 100,000 g for another 60 min. The resulting supernatant was membrane
fractions. All experiment was conducted at 4°C. The total protein concentration of
these samples is determined using Pierce 660 nm Protein Assay Reagents
(ThermoFisher).
Western blotting analysis. Western blotting was used to identify and semiquantify proteins of interest isolated from the above samples. Thirty micrograms of
total protein premixed with Laemmli buffer (Bio-Rad) containing 0.1% βmercaptoethanol was loaded per well for sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE, Bio-Rad 4-20% Mini-PROTEAN TGX Precast Protein
Gel). The proteins were transblotted on Bio-Rad PVDF membrane at 120 V for ~ 70
min. After the transfer, the membrane was blocked for 2 h in 1x Tris-buffered saline
with 0.1% of Tween 20 (TBST) and 8% nonfat dry milk at room temperature. The
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membrane was then incubated with mouse anti-ATP7B monoclonal antibody (1:500,
Santa Cruz) or mouse anti-β-Actin monoclonal antibody (1:5,000, Sigma) in TBST
overnight at 4°C. After TBST-washing, the membrane was incubated with goat antimouse HRP secondary antibody (1:10,000, Novex) for 1 hour at room temperature.
The membrane was then washed and incubated with an ECL fluorescence kit (BioRad Clarity™ Western ECL Substrate) or SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo scientific). Membranes were exposed in Gel Logic 2200
Pro and were qualified with ImageQuant TL Image Analysis Software (GE
Healthcare). Levels of β-Actin were used to normalize ATP7B expression in cytosol
and membrane. For Western blotting analysis of the nanoparticle-bound complement
C3 and C5, rat anti-mouse Complement C3 monoclonal antibody (1:200, Santa Cruz),
rat anti-mouse Complement C5a monoclonal antibody (1:200, MyBioSource), and
goat anti-rat HRP secondary antibody (1:10,000, Santa Cruz) were used.
Quantitative real-time PCR for Atp7b mRNA analysis in mouse
hepatocytes. Total RNA from the perfused primary hepatocytes in mouse at different
times following injection of PEG-HCuSNPs (20 mg/kg of Cu) was isolated using
RNA-Bee reagent (AMS Biotechnology) according to the manufacturer's protocol.
The RNA was quantified by measuring its absorbance at 280 nm with a UV-visible
spectrophotometer (NanoDrop ND 1000, ThermoFisher). All the samples were diluted
to 500 ng/µL concentration. The first-strand cDNA was synthesized using GoScript
Reverse Transcription System (Promega). The cDNAs were diluted six times with
water and subjected to real-time PCR using TaqMan Gene Expression Assay,
following the instructions of the manufacturer. The TaqMan assay mixture for mouse
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ATP7B

(assay

ID:

Mm00599675_m1)

and

glyceraldehyde-3-phosphate

dehydrogenase (GAPDH, assay ID: Mm99999915_g1) were purchased from
ThermoFisher. Transcript levels of ATP7B were normalized against to GAPDH
levels. Amplification and quantification were done with a ViiA7 Real-Time PCR
System (Applied Biosystems).

Conflict of Interest: The authors declare no competing financial interest.

Supporting Information Available: Characterization and dissociation of PEGHCuSNPs, release of FITC from the FITC-conjugated HCuSNPs and Western blotting
analysis of ATP7B.

Acknowledgment. The authors thank Richard Kingsley from the University of Rhode
Island for assisting in TEM of nanoparticles, Carol Ayala from Rhode Island Hospital
and Xinran Liu from Yale University for assisting in preparation and TEM of liver
tissue samples, and James Clifton from Brown University for assisting in proteomic
analysis. This work was partially supported by the 973 project of China
(2013CB932500), the award of the “National Youth Thousand Talents Plan” of China,
the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai
Institutions of Higher Learning (No.2012-05), and by grants from the National
Institute of Health (R01EB018748, P20GM103430 and P20GM104937).

	
  

	
  

57	
  

References
1.

Li, Y.; Lu, W.; Huang, Q.; Huang, M.; Li, C.; Chen, W., Copper sulfide

nanoparticles for photothermal ablation of tumor cells. Nanomedicine (Lond) 2010, 5,
1161-71.
2.

Tian, Q.; Jiang, F.; Zou, R.; Liu, Q.; Chen, Z.; Zhu, M.; Yang, S.; Wang, J.;

Wang, J.; Hu, J., Hydrophilic Cu9S5 nanocrystals: a photothermal agent with a 25.7%
heat conversion efficiency for photothermal ablation of cancer cells in vivo. ACS
Nano 2011, 5, 9761-71.
3.

Tian, Q.; Tang, M.; Sun, Y.; Zou, R.; Chen, Z.; Zhu, M.; Yang, S.; Wang, J.;

Wang, J.; Hu, J., Hydrophilic flower-like CuS superstructures as an efficient 980 nm
laser-driven photothermal agent for ablation of cancer cells. Adv Mater 2011, 23,
3542-7.
4.

Xiao, Z., CuS nanoparticles: clinically favorable materials for photothermal

applications? Nanomedicine. 2014, 9, 373-5.
5.

Ramadan, S.; Guo, L.; Li, Y.; Yan, B.; Lu, W., Hollow copper sulfide

nanoparticle-mediated transdermal drug delivery. Small 2012, 8, 3143-50.
6.

Guo, L.; Yan, D. D.; Yang, D.; Li, Y.; Wang, X.; Zalewski, O.; Yan, B.; Lu,

W., Combinatorial photothermal and immuno cancer therapy using chitosan-coated
hollow copper sulfide nanoparticles. ACS Nano 2014, 8, 5670-81.
7.

Dong, K.; Liu, Z.; Li, Z.; Ren, J.; Qu, X., Hydrophobic anticancer drug

delivery by a 980 nm laser-driven photothermal vehicle for efficient synergistic
therapy of cancer cells in vivo. Adv Mater 2013, 25, 4452-8.

	
  

	
  

58	
  

8.

Ku, G.; Zhou, M.; Song, S.; Huang, Q.; Hazle, J.; Li, C., Copper sulfide

nanoparticles as a new class of photoacoustic contrast agent for deep tissue imaging at
1064 nm. ACS Nano 2012, 6, 7489-96.
9.

Wang, Z.; Huang, P.; Jacobson, O.; Wang, Z.; Liu, Y.; Lin, L.; Lin, J.; Lu, N.;

Zhang, H.; Tian, R., et al., Biomineralization-Inspired Synthesis of Copper SulfideFerritin Nanocages as Cancer Theranostics. ACS Nano 2016, 10, 3453-60.
10.

Zhou, M.; Zhang, R.; Huang, M.; Lu, W.; Song, S.; Melancon, M. P.; Tian, M.;

Liang, D.; Li, C., A chelator-free multifunctional [64Cu]CuS nanoparticle platform for
simultaneous micro-PET/CT imaging and photothermal ablation therapy. J Am Chem
Soc 2010, 132, 15351-8.
11.

Zhou, M.; Li, J.; Liang, S.; Sood, A. K.; Liang, D.; Li, C., CuS Nanodots with

Ultrahigh Efficient Renal Clearance for Positron Emission Tomography Imaging and
Image-Guided Photothermal Therapy. ACS Nano, 2015, 9, 7085-96.
12.

Chen, F.; Hong, H.; Goel, S.; Graves, S. A.; Orbay, H.; Ehlerding, E. B.; Shi,

S.; Theuer, C. P.; Nickles, R. J.; Cai, W., In Vivo Tumor Vasculature Targeting of
CuS@MSN Based Theranostic Nanomedicine. ACS Nano 2015, 9, 3926-34.
13.

Xiao, Q.; Zheng, X.; Bu, W.; Ge, W.; Zhang, S.; Chen, F.; Xing, H.; Ren, Q.;

Fan, W.; Zhao, K., et al., A core/satellite multifunctional nanotheranostic for in vivo
imaging and tumor eradication by radiation/photothermal synergistic therapy. J Am
Chem Soc 2013, 135, 13041-8.
14.

Zha, Z.; Zhang, S.; Deng, Z.; Li, Y.; Li, C.; Dai, Z., Enzyme-responsive copper

sulphide nanoparticles for combined photoacoustic imaging, tumor-selective
chemotherapy and photothermal therapy. Chem Commun (Camb) 2013, 49, 3455-7.

	
  

	
  

59	
  

15.

Zhou, M.; Chen, Y.; Adachi, M.; Wen, X.; Erwin, B.; Mawlawi, O.; Lai, S. Y.;

Li, C., Single agent nanoparticle for radiotherapy and radio-photothermal therapy in
anaplastic thyroid cancer. Biomaterials 2015, 57, 41-9.
16.

Zha, Z.; Wang, S.; Zhang, S.; Qu, E.; Ke, H.; Wang, J.; Dai, Z., Targeted

delivery of CuS nanoparticles through ultrasound image-guided microbubble
destruction for efficient photothermal therapy. Nanoscale 2013, 5, 3216-9.
17.

Scheiber, I.; Dringen, R.; Mercer, J. F., Copper: effects of deficiency and

overload. Met Ions Life Sci 2013, 13, 359-87.
18.

Wang, Z.; von dem Bussche, A.; Kabadi, P. K.; Kane, A. B.; Hurt, R. H.,

Biological and environmental transformations of copper-based nanomaterials. ACS
Nano 2013, 7, 8715-27.
19.

Guo, L.; Panderi, I.; Yan, D. D.; Szulak, K.; Li, Y.; Chen, Y. T.; Ma, H.;

Niesen, D. B.; Seeram, N.; Ahmed, A., et al., A comparative study of hollow copper
sulfide nanoparticles and hollow gold nanospheres on degradability and toxicity. ACS
Nano 2013, 7, 8780-93.
20.

Pilot Study of Aurolase(Tm) Therapy in Refractory and/or Recurrent Tumors

of the Head and Neck. http://clinicaltrials.gov/show/NCT00848042
21.

Efficacy Study of Aurolase Therapy in Subjects with Primary and/or

Metastatic Lung Tumors. http://clinicaltrials.gov/show/NCT01679470
22.

Sharifi, S., Behzadi, S., Laurent, S., Forrest, M. L., Stroeve, P., & Mahmoudi,

M. (2012). Toxicity of nanomaterials. Chemical Society Reviews, 41(6), 2323–2343.
http://doi.org/10.1039/c1cs15188f 23. Chem Soc Rev. 2012; 41:2323–2343. [PubMed:
22170510]
	
  

	
  

60	
  

24.

Sadauskas, E., Danscher, G., Stoltenberg, M., Vogel, U., Larsen, A., Wallin, H.

Protracted Elimination of Gold Nanoparticles from Mouse Liver. Nanomedicine. 2009;
5:162–169.
25.

Balasubramanian, S., Jittiwat, J., Manikandan, J., Ong, C., Yu, L., Ong, W.

Biodistribution of Gold Nanoparticles and Gene Expression Changes in the Liver and
Spleen after Intravenous Administration in Rats. Biomaterials. 2010; 31:2034–2042.
26.

Nirmala, G., Akila, S., Nadar, M., Narendhirakannan, R., Chatterjeeb, S.

Biosynthesized Vitis vinifera seed gold nanoparticles Induce apoptotic cell death in
A431 skin cancer cells, RSC Adv. 6 (2016) 82205-82218.
27.

Cho, W.; Cho, M.;Jeong, J.; et al., Acute toxicity and pharmacokinetics of 13

nm-sized PEG-coated gold nanoparticles, Toxicol. Appl. Pharmacol. 236 (2009) 16-24.
28.

De Jaeghere, F.; Allemann, E.; Leroux, J. C.; Stevels, W.; Feijen, J.; Doelker,

E.; Gurny, R., Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide)
nanoparticles: influence on physical stability and in vitro cell uptake. Pharm Res 1999,
16, 859-66.
29.

Doğan, A.; Köseoğlu, F.; Kılıç, E., The Stability Constants of Copper (II)

Complexes with Some α-Amino Acids in Dioxan–Water Mixtures. Analytical
biochemistry 2001, 295, 237-239.
30.

Rigo, A.; Corazza, A.; di Paolo, M. L.; Rossetto, M.; Ugolini, R.; Scarpa, M.,

Interaction of copper with cysteine: stability of cuprous complexes and catalytic role
of cupric ions in anaerobic thiol oxidation. Journal of inorganic biochemistry 2004, 98,
1495-1501.

	
  

	
  

61	
  

31.

Luza, S. C.; Speisky, H. C., Liver copper storage and transport during

development: implications for cytotoxicity. The American journal of clinical nutrition
1996, 63, 812S-820S.
32.

Wang, Z.; Von Dem Bussche, A.; Kabadi, P. K.; Kane, A. B.; Hurt, R. H.,

Biological and environmental transformations of copper-based nanomaterials. ACS
nano 2013, 7, 8715-8727.
33.

Polishchuk, E. V.; Concilli, M.; Iacobacci, S.; Chesi, G.; Pastore, N.; Piccolo,

P.; Paladino, S.; Baldantoni, D.; van, I. S. C.; Chan, J., et al., Wilson disease protein
ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis. Dev Cell 2014,
29, 686-700.
34.

Hasan, N. M.; Gupta, A.; Polishchuk, E.; Yu, C. H.; Polishchuk, R.; Dmitriev,

O. Y.; Lutsenko, S., Molecular events initiating exit of a copper-transporting ATPase
ATP7B from the trans-Golgi network. J Biol Chem 2012, 287, 36041-50.
35.

Nyasae, L. K.; Schell, M. J.; Hubbard, A. L., Copper directs ATP7B to the

apical domain of hepatic cells via basolateral endosomes. Traffic 2014, 15, 1344-65.
36.

Bucci, C.; Thomsen, P.; Nicoziani, P.; McCarthy, J.; van Deurs, B., Rab7: a

key to lysosome biogenesis. Mol Biol Cell 2000, 11, 467-80.
37.

Shi, D.; Yang, D.; Yan, B., Dexamethasone transcriptionally increases the

expression of the pregnane X receptor and synergistically enhances pyrethroid
esfenvalerate in the induction of cytochrome P450 3A23. Biochem Pharmacol 2010,
80, 1274-83.

	
  

	
  

62	
  

38.

Yang, D.; Yang, J.; Shi, D.; Xiao, D.; Chen, Y. T.; Black, C.; Deng, R.; Yan,

B., Hypolipidemic agent Z-guggulsterone: metabolism interplays with induction of
carboxylesterase and bile salt export pump. J Lipid Res 2012, 53, 529-39.
39.

Lorinczi, E.; Tsivkovskii, R.; Haase, W.; Bamberg, E.; Lutsenko, S.; Friedrich,

T., Delivery of the Cu-transporting ATPase ATP7B to the plasma membrane in
Xenopus oocytes. Biochim Biophys Acta 2008, 1778, 896-906.
40.

Cuillel, M.; Chevallet, M.; Charbonnier, P.; Fauquant, C.; Pignot-Paintrand, I.;

Arnaud, J.; Cassio, D.; Michaud-Soret, I.; Mintz, E., Interference of CuO
nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.
Nanoscale 2014, 6, 1707-15.
41.

Walkey, C. D.; Chan, W. C., Understanding and controlling the interaction of

nanomaterials with proteins in a physiological environment. Chemical Society
Reviews 2012, 41, 2780-2799.
42.

Chonn, A.; Semple, S.; Cullis, P., Association of blood proteins with large

unilamellar liposomes in vivo. Relation to circulation lifetimes. Journal of Biological
Chemistry 1992, 267, 18759-18765.
43.

Owens,

D.

E.;

Peppas,

N.

A.,

Opsonization,

biodistribution,

and

pharmacokinetics of polymeric nanoparticles. International journal of pharmaceutics
2006, 307, 93-102.
44.

Vonarbourg, A.; Passirani, C.; Saulnier, P.; Simard, P.; Leroux, J.; Benoit, J.,

Evaluation of pegylated lipid nanocapsules versus complement system activation and
macrophage uptake. Journal of biomedical materials research Part A 2006, 78, 620628.

	
  

	
  

63	
  

45.

Karmali, P. P.; Simberg, D., Interactions of nanoparticles with plasma proteins:

implication on clearance and toxicity of drug delivery systems. Expert opinion on drug
delivery 2011, 8, 343-357.
46.

Qin, X.; Gao, B., The complement system in liver diseases. Cell Mol Immunol

2006, 3, 333-340.
47.

You, J.; Zhou, J.; Zhou, M.; Liu, Y.; Robertson, J. D.; Liang, D.; Van Pelt, C.;

Li, C., Pharmacokinetics, clearance, and biosafety of polyethylene glycol-coated
hollow gold nanospheres. Part Fibre Toxicol 2014, 11, 26.
48.

Kumar, V., Target-oriented drug delivery systems. In Modern Pharmaceutics,

Florence, A. T.; Siepmann, J., Eds. Informa Healthcare: New York, 2009; Vol. 2, pp
329-398.
49

Saab, L., Peluso, J., Muller, C., Ubeaud-Sequier, G. Implication of hepatic

transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic druginduced hepatotoxicity investigated by microvolume cytometry, Cytometry Part A,
vol. 83, no. 4, pp. 403–408, 2013.
50.

Ramadan, S.; Guo, L.; Li, Y.; Yan, B.; Lu, W. Hollow Copper Sulfide

Nanoparticle-Mediated Transdermal Drug Delivery. Small 2012, 8, 3143–3150.
51.

Nikoobakht, B.; El-Sayed, M.A., Preparation and Growth Mechanism of Gold

Nanorods (NRs) Using Seed-Mediated Growth Method. Chem. Mater. 2003, 15,
1957-1962.
52.

Gou L.; Murphy, C., Fine-Tuning the Shape of Gold Nanorods. Chem. Mater.

2005, 17, 3668-3672.

	
  

	
  

64	
  

53.

Huang, X.; Neretina, S.; El-Sayed, M. A., Gold Nanorods: From Synthesis and

Properties to Biological and Biomedical Applications. Adv. Mater. 2009, 21,
4880−4910.
54.

Turkevich, J.; Stevenson, P; Hillier, J., A study of the nucleation and growth

processes in the synthesis of colloidal gold. Discuss. Faraday Soc., 1951,11, 55-75.
DOI:10.1039/DF9511100055
55.

Liang, G.; Jin, X.; Qin, H.; Xing, D., Glutathione-capped, renal-clearable CuS

nanodots for photoacoustic imaging and photothermal therapy. J. Mater. Chem. B,
2017, 5, 6366—6375.
56.

Deng, X.; Kai, L.; Cai, X.; et al. A Hollow‐Structured CuS@Cu2S@Au

Nanohybrid: Synergistically Enhanced Photothermal Efficiency and Photoswitchable
Targeting Effect for Cancer Theranostics[J]. Advanced Materials, 2017.
57.

Kegel, V., Deharde, D., Pfeiffer, E., Zeilinger, K., Seehofer, D., Damm, G.

Protocol for Isolation of Primary Human Hepatocytes and Corresponding Major
Populations of Non-parenchymal Liver Cells. J. Vis. Exp. (109), e53069,
doi:10.3791/53069 (2016).
58.

Liu, W.; Hou, Y.; Chen, H.; Wei, H.; Lin, W.; Li, J.; Zhang, M.; He, F.; Jiang,

Y., Sample preparation method for isolation of single-cell types from mouse liver for
proteomic studies. Proteomics, 11: 3556–3564. doi:10.1002/pmic.201100157.
59.

Tuschl, G.; Hrach, J.; Walter, Y.; Hewitt, PG.; Mueller, S.O., Serum-free

collagen sandwich cultures of adult rat hepatocytes maintain liver-like properties long
term: A valuable model for in vitro toxicity and drug–drug interaction studies. Chem
Biol Interact. 2009; 181:124–137.

	
  

	
  

65	
  

	
  

	
  

66	
  

Figure 1. TEM of bile samples collected from BALB/c mice at different times
following i.v. injection of PEG-HCuSNPs. (A), represent undisintegrated PEGHCuSNPs without injection (Control). Or partially disintegrated large particles after
15min, 1h, 4h, 24h and 48h injection (B) The Cu levels in the supernatant (Cu ions) or
pellet (CuS nanoparticles) of mouse gall bladder. The gall bladders were collected
from BALB/c mice at different times after i.v. injection of PEG-HCuSNPs (20 mg/kg
of Cu). Data are presented as mean ± standard deviation (n = 3 - 4).
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Figure 2. TEM of hepatocytes (A-E) in liver tissues of BALB/c mice at different times
following i.v. injection of PEG-HCuSNPs. Blue arrowheads, partially disintegrated
HCuSNPs; orange arrowheads, large particles with solid structures; green arrowheads,
decomposed small CuS nanoparticles. Structures pseudo-colored in light cyan, bile
canaliculi. Blue arrows, nanoparticle-loaded lysosomes moving toward bile canaliculi.
Nu, nucleus. TEM of Kupffer cells (F-G) in liver tissues of BALB/c mice at different
times following i.v. injection of PEG-HCuSNPs. Structures pseudo-colored in pink,
Kupffer cells. Blue arrowheads, decomposed small CuS nanoparticles. Bars in white,
500 nm; bars in yellow, 100 nm.
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Figure 3. (A), Primarily cultured mouse hepatocytes and Kupffer cells after two steps
collagenase perfusion. Mouse primary hepatocytes were seeded in chamber slide precoated with collagen. The cells were fixed with cold acetone for 5 min followed by
blocking with 10% goat-serum for 30 min at room temperature. The cells were
incubated with RbxMs Anti-Cytokeratin 18 Mab (Abcam, 1:100) at 4oC overnight.
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After PBS washing for three times, the cells were stained with Alexa Fluor 555 goat
anti-rabbit IgG (1:500) for 1 h at room temperature. After PBS washing for 3 times,
the cell nuclei were counterstained with DAPI. Mouse primary Kupffer cells were
separated through incubation with 10 uL phycoerythrin(PE)-conjugated anti-F4/80
antibody in the dark for 15 min at 4oC, and washed with 1 mL BPE. The cell pellet
was then resuspended in 100 uL BPE and incubated with 20 uL anti-PE microbeads
(Miltenyi Biotec) in the dark for 15 min at 4 oC. The cells were seeded on rat tail type
I collagen (Corning, Product #354236) coated coverslips. After 24 h, the cells were
fixed with cold acetone for 5 min. After PBS washing for three times, the cell nuclei
were counterstained with DAPI. Bar, 50 µm. (B), Endocytosis and exocytosis of Cu
by primarily cultured mouse hepatocytes and Kupffer cells. Hepatocytes and kupffer
cells were incubated with PEG-HCuSNPs (10 µg/mL) pretreated with intact mouse
serum for 1 h followed by replacement with fresh media. Cu concentrations in lysate
of hepatocytes and Kupffer cells were analyzed. Data are presented as mean ±
standard deviation (n = 4). (C-E), TEM of hepatocytes at 1 h following incubation
with PEG-HCuSNPs in the presence of 2% intact mouse serum. (C), Distribution of
CuS nanoparticles in cells. White arrows, late endosomes; Arrowheads, lysosomes;
Pink arrows, decomposed CuS nanoparticles in the late endosome; Orange arrows,
decomposed CuS nanoparticles in vacuoles inside the late endosome. (D), Exocytosis
of CuS nanoparticles. Arrowheads, nanoparticles in exosomes with decomposed
nanostructures; Arrows, an exosome being released directly from the cytoplasm
membrane. (E), Multivesicular bodies moving toward cytoplasm membrane and their
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exocytosis. Arrow, CuS nanoparticle-loaded vesicles inside the multivesicular bodies.
Bars, 500 nm.

Figure 4. (A), Immunofluorescence imaging of liver in BALB/c mouse at 1 h after
receiving

i.v.

injection

of

FITC-labeled

PEG-HCuSNPs.

Blue,

late

endosomes/lysosomes immunostained with rabbit anti-Rab7 antibody followed by
CFL405 conjugated donkey anti-rabbit IgG; Green, FITC-labeled CuS nanoparticles;
Red, ATP7B stained with goat anit-ATP7B antibody followed by CFL555 conjugated
donkey anti-goat IgG. Arrows, colocalization of three fluorescences. Bar, 10 µm. (BE), Expression of ATP7B over time in primary hepatocytes isolated from BALB/c
mice after i.v. injection of PEG-HCuSNPs (20 mg/kg of Cu). (B), Western-blotting
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analysis of ATP7B protein levels over time in cytoplasm (Upper row) or on membrane
(Lower row). Three samples collected from three mice at each time point. Control, βactin (Middle row) in cytosol. “0 h”, before injection. (C), Semi-quantitative analysis
of ATP7B expression in (B). The gray scale intensity of each sample was normalized
with that of β-actin expression. Data are presented as mean ± standard deviation (n=3).
**p<0.01, normalized intensity at different times vs. that at 0 h. (D), Quantitative
analysis of Atp7b mRNA levels in hepatocytes over time by real-time PCR. Data are
presented as mean ± standard deviation (n = 4). **p<0.01, normalized intensity at
different times vs. that at 0 h. (E), Western-blot analysis of ATP7B protein adsorbed
on CuS nanoparticles in primary hepatocytes from mice following injection. One
sample was collected from three mice at each time point.
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Figure 5. Western blot analysis of complement C3 (A) and C5 (B) on nanoparticleadsorbed proteins. PEG-HAuNS or PEG-HCuSNPs were incubated for 30 minutes
with 10% freshly collected mouse serum from two mice, followed by centrifugation to
separate nanoparticles (pellet) from the serum (supernatant). Samples were loaded for
Western blotting analysis using rat anti-mouse C3 mAb or rat anti-mouse C5a mAb as
first antibody. Lanes (1) and (7), supernatant from PEG-HAuNS-incubated serum;
Lanes (2) and (8), PEG-HAuNS-bound protein (pellet); Lanes (3) and (9), supernatant
from PEG-HCuSNPs-incubated serum; Lanes (4) and (10), PEG-HCuSNPs-bound
protein (pellet); Lane (6), diluted freshly collected mouse serum; Lane (5), protein
ladders.
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Figure 6. The primarily isolated mouse hepatocyte could form the bile canaliculus and
functional to excrete the HCuSNPs after two days incubation (A), Confocal image of
bile canaliculus after 2 days primarily isolated mouse hepatocyte incubation. Mouse
primary hepatocytes were seeded in 35mm petri-dish pre-coated with rat tail type I
collagen and incubated for 48 hours. Cells were washed twice with 1ml pre-warmed
HBSS (with Ca2+/Mg2+). Then, 1 ml of pre-warmed HBSS (with Ca2+/Mg2+)
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containing 5µM CDFDA was added and incubated cells for 20 minutes in a 37°C
incubator with 5% CO2. At the end of the incubation, aspirated medium and washed
cells twice with 1 ml pre-warmed HBSS (with Ca2+/Mg2+) buffer. Assess cell
morphology and bile canaliculi formation (CDF accumulation in bile canaliculi) with
Zeiss LSM 700 confocal microscope. Bar 100µm. (B), Immunofluorescence imaging
of ATP7B in mouse hepatocytes after two days incubation. Red, ATP7B stained with
goat anit-ATP7B antibody followed by Alexa Fluor 555-conjugated donkey anti-goat
IgG. Blue, DAPI. Bar, 10 µm. (C), Immunofluorescence imaging of HCuSNPs
excretion into bile canaliculus. Green, CDF; Red, PEG-HCuSNP-RITC; Blue,
Hoechst33342-labeled cell nuclei. Arrows, colocalization of two fluorescences. Bar,
10 µm. (D), Immunofluorescence imaging of HCuSNPs colocalized with ATP7B.
Red, ATP7B; Green, PEG-HCuSNP-FITC; Blue, DAPI-labeled cell nuclei. Bar, 10
µm.
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Figure 7. (A), TEM of PEG-HCuSNP@Au. Bar 100nm. (B), Immunofluorescence
imaging of PEG-HCuSNP@Au and PEG-AuNP excretion. Green, CDF; Red, PEGNP-RITC; Blue, Hoechst33342-labeled cell nuclei. Arrows, colocalization of two
fluorescences. (C), Immunofluorescence imaging of PEG-HCuSNP@Au and PEGAuNP localization relative to ATP7B. Red, ATP7B; Green, PEG-NP-FITC; Blue,
DAPI-labeled cell nuclei. Bar, 10 µm. TEM bar for PEG-AuNP is 50nm.
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Figure 8. (A)(B), Comparison of cellular endocytosis and exocytosis between AuNP
and HCuSNP@Au conjugation by mouse primary hepatocytes. 300,000 mouse
primary hepatocytes were seeded on collagen coated 12 mm-insert Transwell
(Corning) for 48h. Before treating the cells, AuNP and HCuSNPs@Au were incubated
in the mouse serum for 1 hour. The final mouse serum concentration in DMEM was
2%. Then mouse serum containing AuNP or HCuSNPs@Au were added to each
transwell to treat the cells for 5 min to test the cellular endocytosis of nanoparticles. In
a separated set of transwells, after treating the cells for 5 min, transwells were washed
and the media was replaced with fresh DMEM plus 10% FBS and incubated with the
cells for another 10, 30, 60 min to determine the cellular exocytosis of AuNP or
HCuSNPs@Au. The mouse serum used in this study was freshly collected from
BALB/C mouse blood in the same day of this experiment. (C)(D), Comparison of
cellular endocytosis and exocytosis between AuNP and HCuSNP@Au by human
primary hepatocytes.
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Figure 9. TEM of bile samples collected from BALB/c mice at 15min, 30min, 1h and
4h following i.v. injection of PEG-HCuSNP@Au. Bars in white, 1µm; Bars in yellow,
100 nm.
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Figure 10. (A) TEM of AuNR@CuS. Bar 40nm. (B-D) Immunofluorescence
imaging of NPs location relative to ATP7B at 5min, 15min and 35min treatment. Red,
ATP7B; Green, PEG-NP-FITC; Blue, DAPI-labeled cell nuclei. (B),HCuSNPs (C),
AuNR (D), AuNR@CuS. (E) Immunofluorescence imaging of NPs excretion into bile
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canaliculus after 35 min incubation. Green, CDF; Red, PEG-NP-RITC; Blue,
Hoechst33342-labeled cell nuclei. Bar is 10µm in (B-E). Arrows, colocalization of
two fluorescences.

Figure 11. (A)(B), Comparison of cellular endocytosis and exocytosis between AuNR
and AuNR@CuS conjugation by mouse primary hepatocytes. 300,000 mouse primary
hepatocytes were seeded on collagen coated 12 mm-insert Transwell (Corning) for
48h. Before treating the cells, AuNR and AuNR@CuS were incubated in the mouse
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serum for 1 hour. The final mouse serum concentration in DMEM was 2%. Then
mouse serum containing AuNR and AuNR@CuS were added to each transwell to treat
the cells for 5 min to test the cellular endocytosis of nanoparticles. In a separated set
of transwells, after treating the cells for 5 min, transwells were washed and the media
was replaced with fresh DMEM plus 10% FBS and incubated with the cells for
another 10, 30, 60 min to determine the cellular exocytosis of AuNR and
AuNR@CuS. The mouse serum used in this study was freshly collected from
BALB/C mouse blood in the same day of this experiment. (C)(D), Comparison of
cellular endocytosis and exocytosis between AuNR and AuNR@CuS conjugation by
human primary hepatocytes.
Table 1. Comparison of the number of proteins absorbed to PEG-HCuSNPs at 5 min
and at 1 h after i.v. injection.*
N (Number of
proteins)

Biological process

	
  

N1 h/N5 min

5 min

1h

Biological adhesion

5

51

10.2

Biological regulation

13

271

20.8

Cell killing

1

7

7.0

Cellular process

14

383

27.4

Developmental process

7

171

24.4

Establishment of localization

6

128

21.3

Growth

1

13

13.0

Immune system process

5

73

14.6
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Viral reproduction

0

4

-

Unknown

23

82

3.6

Rhythmic process

1

7

7.0

Response to stimulus

9

176

19.6

Reproductive process

1

18

18.0

Reproduction

1

20

20.0

Pigmentation

0

1

-

process

10

167

16.7

Multi-organism process

1

29

29.0

Metabolic process

6

251

41.8

Locomotion

2

40

20.0

Localization

7

155

22.1

Multicellular organismal

*Protein classification was based on the biological process in gene ontology terms.
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Table 2. A representative characterization of the 10 most abundant proteins adsorbed
to PEG-HCuSNPs separated from mouse plasma at 5 min after i.v. injection.
Protein

%Spec

1

Complement C3

0.067

2

Ig mu chain C region (Fragment)

0.053

3

Kininogen-1

0.047

4

Potassium voltage-gated channel subfamily KQT member 5

0.020

5

Isoform Kidney of Band 3 anion transport protein

0.020

6

Keratin, type II cytoskeletal 2 oral

0.013

7

Hemoglobin subunit beta-1

0.013

8

Desmoglein-1-alpha

0.013

9

Ankyrin-1

0.013

10

Isoform 2 of Gelsolin

0.013

Table 3. A representative characterization of the 10 most abundant proteins adsorbed
to PEG-HCuSNPs separated from mouse plasma at 1 h after i.v. injection.

	
  

Protein

%Spec

1

Complement C3

1.026

2

Myosin-9

0.894

3

Filamin-A

0.635

4

Hemoglobin subunit alpha

0.485

5

Talin-1

0.409
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6

Hemoglobin subunit beta-1

0.348

7

Actin, cytoplasmic 1

0.309

8

Beta-globin

0.305

9

Serum albumin

0.248

10

ATP synthase subunit beta, mitochondrial

0.240
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Graphical Table of Contents

Scheme 1. (A), Illustration showing two distinct pathways of PEG-HCuSNPs in
hepatocytes and Kupffer cells following i.v. injection. (B), Detailed metabolic process
of PEG-HCuSNPs in (A).
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EXPERIMENTAL SECTION
Dissolution study of PEG-HCuSNPs. PEG-HCuSNPs (0.1 mg/mL of Cu) were
dispersed and incubated in 10 mL of various media in glass vials stirring at 200 rpm.
At predetermined time points, 0.5 mL of samples were transferred to Eppendorf tubes
and centrifuged at 21,130 g. The supernatant were carefully collected for inductively
coupled plasma mass spectrometer (ICP-MS) analysis (Model: X7, Thermo Electron
Corporation) of Cu. The samples were also examined under TEM (JEOL, JEM2100).
Labeling PEG-HCuSNPs with fluorescein isothiocyanate (PEG-HCuSNPs-FITC)
and FITC release. FITC-maleimide solution was added to the PEG-HCuSNPs
suspension to make a final concentration of 1 mg/mL copper and 0.05 mg/mL of
FITC-maleimide. After stirring for 48 h, the obtained PEG-HCuSNPs-FITC were
washed with deionized water 5 times and further with dimethylsulfoxide (DMSO)
twice to remove the unconjugated FITC-maleimide. To test FITC released from PEGHCuSNPs-FITC, PEG-HCuSNPs-FITC were suspended in 10 mL of acetic buffer (pH
4.9) or PBS (7.4) containing 10% mouse serum, and stirred at 200 rpm. At
predetermined time points, 0.5 mL of samples were collected followed by
centrifugation. The fluorescence of FITC in the supernatant was quantified by
microplate reader (Spectramax M2, Ex= 485 nm; Em = 538 nm; cut-off = 530 nm).
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Figure S1. Dissociation of PEG-HCuSNPs (0.1 mg/mL of Cu) in various media at
different time points. (A), The concentration of Cu2+ released from PEG-HCuSNPs in
PBS alone, or PBS supplemented with various amino acids (2 mM). (B), The
concentration of Cu2+ released from PEG-HCuSNPs in PBS alone, or PBS
supplemented with GSH (2 mM) or metallothionine (30 µg/mL). (C-D), TEMs of
PEG-HCuSNPs in PBS containing 2 mM of GSH (C) or in PBS containing 30 µg/mL
of metallothionein (D) after 24-h incubation. Arrowheads, dissociated CuS particles.
Bars, 100 nm. (E), Cu2+ dissolution from PEG-HCuSNPs in acetic buffer (pH 4.9) or
PBS (pH 7.4). Data are presented as mean ± standard deviation (n = 3).
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Figure S2. Cumulative release of FITC from the FITC-conjugated PEG-HCuSNPs
(PEG-HCuSNPs-FITC) in acetate buffer (pH 4.9) (A), or PBS containing 10% mouse
serum (B). Data are presented as mean ± standard deviation (n = 3).

Figure S3. Western-blot analysis of ATP7B protein levels in cytoplasm of hepatocytes
in mice over 15 d after i.v. injection of PEG-HCuSNPs.
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